{"data":[{"public_id":"aubrey-de-grey","name":"Aubrey de Grey","tagline":"SENS Foundation founder and longevity advocacy pioneer.","photo_url":"/api/investor-photos/6e2b955e-1109-4e2a-a375-87b8018671a8.jpg","photo_checked_at":"2026-05-15 11:57:10.067271+00","primary_role":"populariser","roles":["populariser","scientist","philanthropist"],"role_tags":["populariser","scientist","philanthropist","entrepreneur"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"He made SENS-style damage repair a durable longevity agenda: 325 works, 4,733 citations, and public pushes for political attention. Not proof of therapies. Proof of agenda-setting.","overall_score":52,"total_capital_moved":132400000,"updated_at":"2026-06-13 00:02:42.337815+00","scores":[{"dimension":"bravery_conviction","score":8,"rationale_summary":"Aubrey de Grey has strong evidence for bravery/conviction through public contrarian advocacy for treating aging as mutable and for extreme life extension, sustained defense of anti-deathist/longevity positions, and an early damage-repair strategy that later became more broadly accepted. The evidence is especially strong for public and field-level conviction, though less complete for personal sacrifice, financial downside, or self-experimentation.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":4,"rationale_summary":"Capital deployment applies because the evidence indicates longevity institution-building roles, but the provided record contains no disclosed personal investments, donations, fund allocations, or high-confidence amounts. The strongest capital-related signal is founding/co-founding longevity organizations, yet that is only weakly corroborated here and does not establish scale of capital deployed.","confidence":"low","n_a_reason":null},{"dimension":"future_vision","score":10,"rationale_summary":"Aubrey de Grey has repeatedly articulated a highly ambitious, concrete, and durable vision centered on defeating aging, reversing age-related decline, and achieving longevity escape velocity. The evidence includes explicit public mission language, a named book-length vision, organizational research programs, and consistent advocacy framing over time.","confidence":"high","n_a_reason":null},{"dimension":"field_creation","score":8,"rationale_summary":"The evidence directly attributes creation or co-creation of multiple longevity-relevant organizations to de Grey, including SENS Research Foundation, Methuselah Foundation, LEV Foundation, and Repair Biotechnologies. That is strong field-creation evidence because these are organizational vehicles and categories for rejuvenation-focused work. Confidence is limited by sparse independent corroboration of the founding roles and limited evidence about downstream scale or durability.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"The evidence supports substantial field-building leverage: de Grey is credited with founding four longevity-related organizations, has a sizable citation footprint, and is linked to advocacy and policy attention around biomedical gerontology. This indicates influence beyond direct research output, though the provided evidence is stronger for institution-building and intellectual visibility than for independently documented capital attraction, founder formation, or downstream project outcomes.","confidence":"medium","n_a_reason":null},{"dimension":"strategic_taste","score":8,"rationale_summary":"Aubrey de Grey shows strong strategic_taste evidence through a coherent, high-risk, field-building thesis around rejuvenation biotechnology: create nonprofit institutions, promote comprehensive prevention/reversal of age-related disease, and run translational programs such as combined rejuvenation interventions in mice and organ/tissue cryopreservation. The evidence supports early, contrarian, thesis-driven bets that plausibly opened paths in longevity research and advocacy, though it is largely self-published and lacks strong independent counterfactual validation or dated evidence for some earlier institutional bets.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":7,"rationale_summary":"Aubrey de Grey has clear scientific impact by citation-weighted evidence, but the bibliometrics indicate influential agenda-setting work rather than top-tier field-defining citation dominance. OpenAlex reports h-index 29, 4,733 citations, and several moderately cited foundational or conceptual aging/SENS works, with the most-cited work at 352 citations. This supports substantial influence on the longevity research agenda, especially through rejuvenation and mitochondrial/free-radical theory framing, but falls short of a 9-10 profile because there is no evidence here of very highly cited primary discoveries, clinical translation, or landmark experimental programs.","confidence":"high","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/aubrey-de-grey"},{"public_id":"cynthia-kenyon","name":"Cynthia Kenyon","tagline":"Her C. elegans daf-2 longevity work helped establish aging as genetically regulable and catalyzed modern aging-biology research; later led aging research at Calico.","photo_url":"/api/investor-photos/6f5ae469-348e-4e37-b9f4-f3effe9ea8ba.jpg","photo_checked_at":"2026-06-05 22:45:04.275925+00","primary_role":"scientist","roles":["scientist","entrepreneur","operator"],"role_tags":["scientist","entrepreneur","operator","self-experimenter"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Kenyon helped prove aging is not mystical wear-and-tear: a single daf-2 mutation doubled worm lifespan. That result made genetic control of longevity a serious field, not a fringe wish.","overall_score":45,"total_capital_moved":0,"updated_at":"2026-06-13 00:02:46.893935+00","scores":[{"dimension":"field_creation","score":4,"rationale_summary":"The dimension applies, but the evidence for field creation is limited. Kenyon is credited with co-founding Elixir Pharmaceuticals, giving some organization-building signal, and she participated in a consensus workshop/publication that helped frame aging interventions for human translation. However, the provided evidence does not show that she created a durable program, funding path, protocol, or community infrastructure at field-defining scale.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":6,"rationale_summary":"Kenyon has a clear and durable public scientific vision that aging is biologically plastic and potentially actionable for extending healthy human lifespan, grounded in her long-running genetics-of-aging work and translational framing. However, the evidence provided is stronger for scientific vision and research direction than for a highly specific public roadmap to ending aging, reversing decline, or achieving human lifespan extension on a defined path or timeline.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":3,"rationale_summary":"There is credible but sparse evidence that Kenyon directed longevity-relevant research resources through NIH-funded projects and institution-building roles, including co-founding Elixir and later leading aging research at Calico. However, the evidence does not show personal capital deployed, disclosed funding amounts, recurring philanthropy, or independently quantified resource allocation, so the score should remain low.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":9,"rationale_summary":"Kenyon shows unusually strong strategic taste for longevity: she made an early, thesis-coherent bet that aging was genetically regulable, pursued it through C. elegans genetics, expanded into conserved insulin/IGF-1 and hormone signaling mechanisms, and later moved toward human gene perturbation, aging-cancer translation, institutional platform-building, and company formation. The evidence supports a field-defining strategic pattern, though some organizational and counterfactual details are thin.","confidence":"high","n_a_reason":null},{"dimension":"bravery_conviction","score":6,"rationale_summary":"Kenyon has credible evidence of public conviction around aging/life-extension science: she pursued and published lifespan-extension genetics unusually early, later explicitly framed hormone research as relevant to life extension, and co-authored a public argument about readiness for human anti-aging interventions. However, the evidence does not show major personal downside, sustained criticism, financial sacrifice, or self-experimentation, so the score should be solid but not near the top of the scale.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9,"rationale_summary":"Cynthia Kenyon has field-defining scientific impact in longevity biology. The primary citation-metrics evidence is strong: h-index 80, nearly 40,000 citations, and multiple highly cited aging/longevity papers, including the landmark 1993 C. elegans daf-2 mutant paper with 3,439 citations. The cited work directly shaped the genetic regulation of aging and insulin/IGF-1 longevity pathway agenda, which is central to modern aging biology. Lack of clinical trials limits translational impact but does not materially weaken the scientific-impact score.","confidence":"high","n_a_reason":null},{"dimension":"multiplier_effect","score":8,"rationale_summary":"Kenyon shows strong second-order leverage through exceptionally high citation impact around foundational aging-genetics work, indicating broad follow-on research activity and field legitimacy. The founding of Elixir Pharmaceuticals and later aging leadership at Calico further support translation and institution-building, though the evidence gives limited detail on capital attracted, programs built, or direct downstream outcomes.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/cynthia-kenyon"},{"public_id":"george-church","name":"George Church","tagline":"Led and founded major synthetic biology and genomics efforts with public work on aging reversal, gene therapy, and longevity biotechnology companies including Rejuvenate Bio.","photo_url":"/api/investor-photos/403b6f88-9953-4635-988f-77baffc8dda2.jpg","photo_checked_at":"2026-06-05 23:15:01.578776+00","primary_role":"scientist","roles":["scientist","entrepreneur","investor"],"role_tags":["scientist","entrepreneur","investor"],"theme_tags":["destination","meta_view","path","risk_view"],"impact_statement":"Church helped make longevity a genomics problem: aging-expression signatures, naked mole-rat transcriptomics, and screen pipelines. Not immortality dust; useful machinery.","overall_score":44,"total_capital_moved":0,"updated_at":"2026-06-13 00:02:52.382791+00","scores":[{"dimension":"scientific_impact","score":6,"rationale_summary":"Scientific impact applies. The evidence includes primary academic papers with Church as coauthor in aging biology, transcriptomics, naked mole-rat longevity biology, and large-scale RNAi screening methods. A citation-metrics source reports a high h-index, large citation total, and many works, which would normally support a strong score, but the source text says the OpenAlex match is for Feng Zhang and lists most-cited works that do not clearly correspond to George Church, so it cannot cleanly justify a field-defining score for this hero.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":2,"rationale_summary":"There is sparse evidence of longevity-relevant institution-building through Church's claimed co-founding of Rejuvenate Bio, but no disclosed personal capital, donations, fund allocation, or quantified philanthropic/resource deployment. The only direct capital-related evidence is self-published and promotional, so it cannot support a score above 5 and in practice supports only a low score.","confidence":"low","n_a_reason":null},{"dimension":"future_vision","score":8,"rationale_summary":"George Church has substantial evidence of a durable and concrete future vision around aging reversal, rejuvenation therapies, gene therapy, tissue reprogramming, and longevity biotechnology. The evidence includes multiple destination-oriented statements about reversing age-related phenotypes and improving healthspan, several path-oriented technical strategies, and public association with Rejuvenate Bio's age-reversal gene therapy framing. The score is not higher because much of the evidence is summarized or broad, and the provided primary sources include limited direct long-form vision statements from Church himself.","confidence":"medium","n_a_reason":null},{"dimension":"strategic_taste","score":8,"rationale_summary":"Church shows strong strategic taste through a coherent, high-risk platform thesis: build foundational genomics, genome engineering, and synthetic biology capabilities, then translate them into companies and public projects relevant to gene therapy, aging reversal, regenerative medicine, and adjacent frontier biology. The evidence supports early and counterfactually important bets such as the Personal Genome Project, BRAIN Initiative, eGenesis, and Rejuvenate Bio. The score is held below field-defining maximum because much of the evidence is self-published, some bet timing and counterfactual impact are underspecified, and direct longevity outcomes remain only partially evidenced here.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":7,"rationale_summary":"Field creation clearly applies: the evidence credits Church with founding or co-founding multiple biotech organizations relevant or adjacent to longevity, especially Rejuvenate Bio, and with contributing to field-level research infrastructure and classification work. The score is strong but not maximal because the organization evidence is partly duplicated/seeded from investor dossier notes, only one founded organization is marked active, and the supplied evidence does not fully document the downstream field-wide impact of these entities.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":6,"rationale_summary":"The evidence supports a moderate bravery/conviction score. Church publicly attached his reputation to longevity-adjacent and fringe-adjacent areas, especially cryonics-related structural brain preservation and age-related disease reversal through RejuvenateBio. However, the record provided shows limited evidence of personal downside, sustained criticism, large personal risk, or direct self-experimentation, so it does not justify a high score.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"The dimension applies: the evidence shows Church created or co-founded multiple biotechnology organizations and public projects that plausibly attracted collaborators, founders, capital, and follow-on work beyond his own lab output. The strongest multiplier signal is organizational: Rejuvenate Bio, eGenesis, Matter Bio, and Colossal indicate repeated translation of platform biology into companies. However, the evidence is uneven, includes duplicate organization entries, and some citation metrics appear mismatched to Feng Zhang rather than Church, so the score is high but not field-defining on this record alone.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/george-church"},{"public_id":"valter-longo","name":"Valter Longo","tagline":"Biogerontologist translating fasting biology into longevity interventions","photo_url":"/api/investor-photos/eacfc0cc-53e0-40b4-b702-941657ce2e7e.jpg","photo_checked_at":"2026-09-04 19:46:22.545216+00","primary_role":"scientist","roles":["scientist"],"role_tags":["scientist"],"theme_tags":["meta_view","path"],"impact_statement":"Longo helped move fasting biology from aging mechanisms into fasting-mimicking diets and human trials. His 348 works have drawn 37,268 citations, though clinical adoption remains unproven.","overall_score":43.75,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":7,"rationale_summary":"Longo presents a durable, translational vision of extending healthy lifespan by modulating conserved nutrient-sensing and stress-resistance pathways, particularly through periodic fasting-mimicking diets. The vision is scientifically specific and consistently reflected across his research, but the evidence lacks a clearly stated destination, quantitative lifespan target, development timeline, or comprehensive account of risks and barriers.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The evidence documents substantial scientific activity but identifies no investments, donations, catalytic positions, or capital-backed longevity outcomes to evaluate under this dimension.","confidence":"high","n_a_reason":"No public investment or donation activity is evidenced; the record characterizes Longo as a scientist rather than a capital deployer."},{"dimension":"field_creation","score":5,"rationale_summary":"Longo has made fasting-mimicking diets a recognizable translational protocol and is associated with institutional and commercial vehicles for longevity research. However, the supplied evidence does not independently establish that he founded the USC Longevity Institute or L-Nutra, nor demonstrate their scale, activity, or broader field-building effects.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9,"rationale_summary":"OpenAlex metrics indicate field-defining scientific influence: an h-index of 89, 37,268 citations, and numerous highly cited works spanning foundational aging mechanisms, fasting biology, nutrition, and human health. Multiple papers have received roughly 700–3,000 citations, demonstrating sustained influence beyond publication volume. The evidence supports exceptional impact, though not a perfect score because no clinical trials were identified and the supplied recent papers do not independently establish broad clinical adoption.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":6.5,"rationale_summary":"Longo shows a coherent, sustained strategy linking nutrient-sensing and fasting biology to practical interventions across aging and disease. The progression from foundational yeast research to fasting-mimicking diets and clinical applications suggests strong thesis formation and translational judgment. However, the supplied evidence does not establish how early or contrarian these choices were, demonstrate clear counterfactual field impact, or substantiate L-Nutra's founding and outcomes.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":3,"rationale_summary":"Longo shows limited but credible contrarian conviction by publicly advancing a framework that challenges conventional aging-centered thinking and by sustaining a research program around fasting-based interventions. However, the evidence does not establish serious personal risk, career sacrifice, sustained resistance to public criticism, or self-experimentation.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Longo demonstrates substantial second-order leverage through a highly influential research corpus, extensive cross-institutional collaboration, leadership of the USC Longevity Institute, and creation of L-Nutra as a vehicle for translating fasting research beyond academia. However, the evidence does not establish field-defining effects on capital, policy, talent formation, or founder creation.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/valter-longo"},{"public_id":"marco-demaria","name":"Marco Demaria","tagline":"Cellular-senescence researcher mapping its roles across aging and disease","photo_url":"/api/investor-photos/56db9a1b-9900-45a0-9838-040861f6f223.jpg","photo_checked_at":"2026-09-11 20:15:03.165591+00","primary_role":"scientist","roles":["scientist","entrepreneur"],"role_tags":["scientist","entrepreneur"],"theme_tags":["destination","meta_view","path","risk_view"],"impact_statement":"Demaria helped define how senescent cells can aid wound healing yet drive age-related disease, then advanced their use as biomarkers and therapeutic targets.","overall_score":42.82,"total_capital_moved":0,"updated_at":"2026-09-11 20:15:03.165591+00","scores":[{"dimension":"future_vision","score":7.5,"rationale_summary":"Demaria presents a durable translational vision in which senescence biology enables rejuvenating interventions, longer healthspan, and healthcare organized around biological aging. The vision includes actionable priorities such as validated biomarkers, adaptive trials, monitoring platforms, and selective senotherapeutics. It is ambitious and repeated across research and healthcare contexts, but stops short of a clearly defined program, timeline, or explicit commitment to ending aging or substantially extending maximum human lifespan.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The record contains no investments, donations, disclosed capital totals, catalytic positions, or backed companies with independently rated clinical outcomes. The cited research achievements concern scientific impact rather than capital deployment, so this dimension is inapplicable on the supplied evidence.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced for this research-focused scientist."},{"dimension":"field_creation","score":3,"rationale_summary":"Demaria reportedly co-founded Cleara Biotech, creating a translational company focused on senescent-cell therapeutics. This is relevant field-building, but the supplied sources do not independently attest the company or demonstrate substantial programs, community infrastructure, funding pathways, or field-wide impact.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":8,"rationale_summary":"Demaria has generated substantial second-order scientific leverage: his work is extensively cited, several papers have become major reference points, and he helped produce field-wide experimental guidelines with a large international coalition. Co-founding Cleara Biotech also extends his research into commercial therapeutics, although the evidence does not establish the company's scale or downstream impact.","confidence":"high","n_a_reason":null},{"dimension":"scientific_impact","score":9.2,"rationale_summary":"Field-defining scientific influence in cellular senescence, supported by an h-index of 59, nearly 29,000 citations, and numerous foundational papers with roughly 1,000–3,300 citations each. The highly cited work spans senescence definitions, wound healing, biomarkers, cancer relapse, and senolytic interventions, indicating broad influence on the field's technical agenda rather than publication volume alone.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":7,"rationale_summary":"Demaria shows a coherent, relatively early thesis spanning the context-dependent biology of cellular senescence and its therapeutic targeting. His work linked senescence to beneficial tissue repair as well as aging-related pathology, while subsequent clearance studies and the 2018 co-founding of Cleara Biotech indicate translation of that thesis toward therapies. However, the evidence does not establish that his choices were uniquely contrarian or counterfactually decisive, and no clinical or independently rated company outcome is provided.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":2,"rationale_summary":"Co-founding Cleara Biotech shows some public commitment to translating senescence research into therapeutics, but the evidence does not establish personal financial exposure, career sacrifice, contrarian advocacy, persistence under serious criticism, or self-experimentation. Scientific prominence and citation impact do not independently demonstrate bravery under this rubric.","confidence":"low","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/marco-demaria"},{"public_id":"alex-zhavoronkov","name":"Alex Zhavoronkov","tagline":null,"photo_url":"/api/investor-photos/5fdf1868-7d3e-462b-916f-e596d3cecdc7.jpg","photo_checked_at":"2026-07-08 15:15:01.942376+00","primary_role":"populariser","roles":["populariser","entrepreneur","scientist"],"role_tags":["populariser","entrepreneur","scientist","philanthropist","investor"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Zhavoronkov helped make AI drug discovery a serious longevity lane, not just conference vapor. His record is strongest in papers and Insilico’s aging-target work, not proven clinical wins.","overall_score":42,"total_capital_moved":0,"updated_at":"2026-07-08 15:15:01.942376+00","scores":[{"dimension":"field_creation","score":6,"rationale_summary":"Zhavoronkov has credible evidence of founding Insilico Medicine, an organization connected to longevity and AI drug discovery, and primary/independent academic evidence shows Insilico producing AI-driven aging and therapeutic-development work. This supports above-average field creation, but the evidence provided is thin on broader ecosystem effects such as creating durable communities, funding paths, standards, or widely adopted protocols.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":2,"rationale_summary":"The dimension applies, but the provided evidence contains little direct proof of public risk-taking or conviction as defined by the rubric. Zhavoronkov is clearly a visible longevity and AI-drug-discovery entrepreneur, ecosystem convenor, researcher, and personal investor, but the evidence does not establish contrarian public stances, career sacrifice, major relative-risk bets, sustained conviction under criticism, or self-experimentation. A low score is warranted for some visible commitment and personal investing, with low confidence because the evidence is thin for this dimension.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Zhavoronkov shows credible multiplier effects through company formation around Insilico Medicine, a large and highly cited publication footprint, and visible collaboration across AI drug discovery, aging biology, and disease areas. The strongest independently corroborated signal is scholarly follow-on influence: OpenAlex reports 19,202 citations, h-index 71, 444 works, and multiple highly cited AI/drug-discovery papers. Evidence for broader leverage through capital attraction, policy attention, founder lineage, or public legitimacy is thinner in the provided record, so the score is strong but not field-defining.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":8,"rationale_summary":"The primary bibliometric evidence indicates substantial scientific influence: OpenAlex reports h-index 71, 19,202 citations, and multiple highly cited works in AI drug discovery, deep learning in biomedicine, de novo molecular design, and aging biomarkers. The most-cited paper has 1,480 citations, and several others exceed 500 citations, suggesting genuine agenda-setting impact rather than mere publication volume. Recent primary PubMed papers show continuing work in aging-focused AI target discovery and aging biology, but the evidence does not show clinical-trial translation attributable to him, which keeps the score below the very top tier.","confidence":"high","n_a_reason":null},{"dimension":"future_vision","score":8,"rationale_summary":"Zhavoronkov has substantial evidence of a concrete and durable future vision centered on AI-driven drug discovery, biological aging as a modifiable process, geroprotectors, aging-related disease targets, and healthspan extension. The vision is ambitious and fairly specific, with repeated public framing around AI, multimodal models, aging clocks, Peakspan, therapeutics for chronic and age-related disease, and biotech infrastructure. It falls short of a top score because the provided evidence is mostly summarized or publication-style statements rather than direct, personal, field-defining destination claims for ending aging or reversing decline outright.","confidence":"high","n_a_reason":null},{"dimension":"capital_deployed","score":4,"rationale_summary":"The dimension applies because the evidence identifies Zhavoronkov as founder/chairman/CEO/CBO of Insilico Medicine and notes at least one direct personal investment related to longevity. However, the disclosed capital amount is unknown, there are no donation totals, and the only direct capital-deployment claim comes from an unknown-independence dossier rather than independently corroborated transaction evidence. Institution-building through Insilico appears longevity-relevant, but the provided evidence does not quantify his own capital at risk or resource allocation enough to justify a high score.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":7,"rationale_summary":"Zhavoronkov shows a coherent and longevity-relevant strategic thesis: building therapeutics through AI drug discovery via Insilico Medicine. The evidence supports pattern coherence and some early/contrarian flavor through AI-enabled drug discovery work tied to aging, with substantial publication traction around deep learning for molecules, biomarkers, and age-related target discovery. However, the record provided does not establish timing, counterfactual importance, stage preference, risk appetite, or whether his choices opened paths others were not seeing, so the score stops short of field-defining.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/alex-zhavoronkov"},{"public_id":"joao-pedro-de-magalhaes","name":"João Pedro de Magalhães","tagline":"Senescence.info founder and aging-database builder.","photo_url":"/api/investor-photos/1ec95150-0cd7-449c-94d7-74ae839d879c.jpg","photo_checked_at":"2026-05-15 11:57:21.624479+00","primary_role":"scientist","roles":["scientist","entrepreneur","philanthropist"],"role_tags":["scientist","entrepreneur","philanthropist"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Magalhães helped build aging biology’s plumbing: genomic and longevity databases that became highly cited tools, not just another pile of anti-aging slogans.","overall_score":42,"total_capital_moved":0,"updated_at":"2026-06-13 00:02:58.01585+00","scores":[{"dimension":"future_vision","score":8,"rationale_summary":"João Pedro de Magalhães has unusually explicit and durable public future-vision evidence: he frames aging biology as manipulable, connects that to interventions preserving health and combating disease, publicly identifies with transhumanist ambitions to exceed current human limits, and has repeated path-level scientific statements about mechanisms, biomarkers, cancer trade-offs, stemness loss, and cryotechnology. The vision is ambitious and public, though somewhat split between broad futurist/transhumanist framing and research-program statements rather than a single detailed roadmap for ending aging.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":8,"rationale_summary":"Primary citation metrics show substantial field-level scientific influence: h-index 74, 18,946 citations, 298 works, and multiple heavily cited papers/databases in aging genomics and longevity resources. The most-cited works indicate both direct scientific contributions and enabling infrastructure for the field, especially Human Ageing Genomic Resources and longevity-record databases. Impact appears strong and agenda-shaping, though not at the very highest field-defining tier because the top-cited works are influential but mostly in the hundreds to low-thousands of citations and there is no clinical/translational trial evidence provided.","confidence":"high","n_a_reason":null},{"dimension":"capital_deployed","score":1,"rationale_summary":"There is no credible evidence of João Pedro de Magalhães deploying personal capital, philanthropy, fund allocations, or disclosed institutional funding toward longevity. The evidence shows scientific, academic, entrepreneurial, CSO, advisory, and database-building activity, but not capital deployment amounts or funding control. Thin evidence supports only a very low score rather than N/A because some institution-building or company roles are present.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Strong bibliometric evidence and repeated highly cited aging-database/resource papers indicate substantial second-order leverage through field infrastructure and follow-on scientific use. His lab and Oxford Cryotechnology add organization-building evidence, but the record here is thin on capital attraction, policy influence, founder creation, or public-legitimacy effects, so this is not field-defining across the full multiplier rubric.","confidence":"medium","n_a_reason":null},{"dimension":"strategic_taste","score":7,"rationale_summary":"The evidence supports a strong strategic_taste score: de Magalhães appears to have pursued a coherent, early, infrastructure-oriented thesis around aging as a manipulable biological process, combining academic lab-building, public aging databases, and later biotech-facing roles. His Human Ageing Genomic Resources and longevity-record database work are especially relevant because they suggest field-enabling knowledge infrastructure rather than only individual papers. However, the evidence is mostly self-published or bibliometric, with limited independent detail on timing, contrarian nature, counterfactual importance, or the specific impact of commercial bets, so the score should not be field-defining.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":5,"rationale_summary":"The dimension applies: the evidence indicates Magalhães founded aging/longevity-oriented entities and maintained Senescence.info-related infrastructure, which supports some field-building credit. However, the usable evidence is mostly self-published or weakly sourced, and the independent sources provided do not corroborate the specific field-creation achievements, so the independence gate caps the score at 5.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":6,"rationale_summary":"The evidence shows repeated public conviction on contested longevity-adjacent positions: ethical defense of longevity research, burden-shifting against critics of anti-aging work, public transhumanist positioning, and serious engagement with structural brain preservation. This supports contrarian stance and sustained public defense, but the record provided does not show major personal sacrifice, severe backlash endured, large personal financial risk, or direct self-experimentation, so the score should be moderate rather than high.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/joao-pedro-de-magalhaes"},{"public_id":"s-jay-olshansky","name":"S. Jay Olshansky","tagline":"Biodemographer defining the limits, economics, and public-health case for longevity","photo_url":"/api/investor-photos/8b72c602-f40d-43a7-8250-75cfd543daad.jpg","photo_checked_at":"2026-09-04 20:03:20.039632+00","primary_role":"scientist","roles":["scientist","entrepreneur"],"role_tags":["scientist","entrepreneur"],"theme_tags":["meta_view","path"],"impact_statement":"Olshansky shaped debates on longevity limits and made delayed aging a public-health and economic case. His 178 works have drawn more than 13,000 citations, including major papers on healthspan and life expectancy.","overall_score":41.42,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"strategic_taste","score":7,"rationale_summary":"The publication record shows a sustained, unusually coherent strategy: defining longevity's limits, anticipating healthspan tradeoffs, and arguing that delayed aging could yield major health and economic returns. The early timing and later influence of these theses support strong strategic taste, although the supplied evidence does not establish catalytic deployment, investment selection, or the counterfactual impact of his organizational choices.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":7,"rationale_summary":"Olshansky has advanced a durable, influential vision centered on slowing biological aging to extend healthspan, supported by the Longevity Dividend framework and a public-health and economic case for redirecting medical research toward delayed aging. The vision is concrete at the strategic level and has been sustained publicly, but the supplied evidence lacks a defined end state, implementation milestones, timelines, or explicit risk analysis.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":2,"rationale_summary":"Olshansky has publicly and persistently advocated shifting research and policy toward slowing aging through the Longevity Dividend, including congressional testimony. However, the supplied evidence does not establish that this advocacy was contrarian at the time, attracted serious criticism, imposed career or financial costs, involved a consequential personal bet, or included self-experimentation.","confidence":"low","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"Olshansky's substantial scholarly influence concerns scientific impact rather than deployed capital. The evidence provides no investments, donations, investees, funding amounts, catalytic positions, or independently corroborated outcomes attributable to his capital.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced: zero investments and zero donations were found, so this dimension is inapplicable."},{"dimension":"scientific_impact","score":8.5,"rationale_summary":"Strong, sustained scientific influence in biodemography and aging research, anchored by an h-index of 43, more than 13,000 citations, and several highly cited papers that shaped debates on life-expectancy limits, epidemiologic transition, healthspan, and the economic value of delayed aging.","confidence":"high","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"Olshansky’s highly cited body of work demonstrates substantial second-order scholarly influence, especially around longevity limits, health disparities, and the economic case for delayed aging. However, the evidence does not directly establish resulting capital flows, policy adoption, talent attraction, or follow-on organizations at field-defining scale.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":5,"rationale_summary":"Olshansky has credible field-building activity through co-founding Lapetus Solutions and helping develop the modern biodemographic paradigm and Longevity Dividend framing. However, the evidence does not demonstrate that these efforts created a large, durable organization, program, community, protocol, or funding pathway with broad uptake, and the company is no longer active.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/s-jay-olshansky"},{"public_id":"peter-de-keizer","name":"Peter de Keizer","tagline":"Senescence researcher developing targeted senolytic therapies","photo_url":"/api/investor-photos/8fb3ed52-b872-4f80-8eaf-6006ea57446a.jpg","photo_checked_at":"2026-09-04 19:30:08.825789+00","primary_role":"scientist","roles":["scientist","entrepreneur"],"role_tags":["scientist","entrepreneur"],"theme_tags":["meta_view","path","risk_view"],"impact_statement":"De Keizer helped establish targeted senescent-cell removal as a longevity strategy. His landmark 2017 paper has 1,456 citations, though human clinical benefit remains unproven.","overall_score":40.83,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":6,"rationale_summary":"De Keizer has articulated a durable and reasonably specific therapeutic vision centered on selectively eliminating senescent cells and designing compounds that also stimulate tissue rejuvenation. This is an ambitious path toward reducing frailty and age-related disease, supported by a sustained FOXO4-p53 research and commercialization program. However, the evidence contains no explicit destination statement, human-lifespan target, development timeline, or comprehensive vision for ending aging or reversing systemic biological decline.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":8,"rationale_summary":"Strong scientific impact driven by a field-shaping senolytics paper with 1,456 citations, supported by nearly 3,000 total citations and several influential FOXO, senescence, and redox-signaling publications. The h-index of 18 is solid rather than exceptional, and impact is concentrated heavily in one landmark work, so the record falls short of broadly field-defining impact at the very highest tier.","confidence":"high","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"Peter de Keizer is evidenced here as a scientist and founder, but the capital_deployed dimension evaluates outcomes from capital he personally allocated. The record contains no qualifying investments, donations, catalytic financing positions, or backed companies, so this dimension is inapplicable rather than merely unsuccessful.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced: no investments or donations were found."},{"dimension":"strategic_taste","score":6,"rationale_summary":"De Keizer shows a coherent progression from foundational FOXO and cellular-stress research to a highly influential targeted senescent-cell elimination strategy and biotechnology translation. This supports credible strategic taste in selecting a tractable, targeted intervention within aging biology. However, the evidence does not establish when Cleara was founded, how early or contrarian the bet was, whether his choices were counterfactually decisive, or whether the therapies achieved meaningful clinical validation.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":5,"rationale_summary":"De Keizer has a credible field-building achievement as founder and managing director of Cleara Biotech, an organization translating senescence research into targeted therapeutic development. This makes longevity work more actionable beyond academia, but the evidence does not establish the company's scale, durability, external influence, successful programs, or field-wide impact.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":4,"rationale_summary":"De Keizer showed moderate contrarian conviction by publicly advancing senescent-cell targeting and tissue rejuvenation when reversing aging was characterized as utopian. However, the evidence does not establish major personal downside, persistence through serious criticism, an unusually large bet relative to his capacity, or self-experimentation.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"De Keizer has generated meaningful second-order leverage through a highly cited senescence study and the founding of Cleara Biotech, extending his research into a therapeutics organization. The evidence supports substantial scholarly follow-on activity, but does not establish broad talent attraction, capital mobilization, policy influence, or a wider founder ecosystem.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/peter-de-keizer"},{"public_id":"james-l-kirkland","name":"James L. Kirkland","tagline":"Geroscientist advancing senolytics from discovery toward the clinic","photo_url":"/api/investor-photos/59539e63-b3ec-4b56-9c24-a6d121d6b024.jpg","photo_checked_at":"2026-09-04 20:03:15.992053+00","primary_role":"scientist","roles":["scientist","operator"],"role_tags":["scientist","operator"],"theme_tags":["meta_view","path"],"impact_statement":"Kirkland helped establish senolytics as a major geroscience strategy, advancing senescent-cell clearance from landmark animal studies to early human trials in kidney and lung disease.","overall_score":40.25,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":6,"rationale_summary":"Kirkland presents a credible and moderately concrete vision in which targeting cellular senescence improves healthspan and prevents or treats multiple age-related diseases. His extensive, sustained senolytics research reinforces the durability of that vision, but the evidence does not show a clearly articulated end state, development timeline, or comprehensive strategy for ending aging or substantially extending human lifespan.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":10,"rationale_summary":"Field-defining scientific impact is demonstrated by exceptional citation weight and multiple foundational, heavily cited papers that shaped cellular-senescence and senolytic research. The record combines an h-index of 114 and 63,474 citations with landmark work spanning target validation, senolytic discovery, animal efficacy, disease mechanisms, and early human translation.","confidence":"high","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"Kirkland's documented achievements concern scientific research and clinical translation, but this dimension evaluates outcomes from capital he personally deployed. The evidence provides no qualifying deployment activity to score.","confidence":"high","n_a_reason":"No evidence that Kirkland personally deployed capital into longevity companies or made longevity-focused donations; the sole listed item is a grant supporting his own research, not an investment by him."},{"dimension":"field_creation","score":1,"rationale_summary":"Field creation is applicable, but the supplied evidence does not show Kirkland founding an organization, program, community, protocol, funding path, or other durable field-building structure. The cited research demonstrates continued scientific participation in senolytics and gerotherapeutics, not creation of infrastructure that made the field more accessible to others.","confidence":"high","n_a_reason":null},{"dimension":"multiplier_effect","score":8,"rationale_summary":"Kirkland's work shows substantial second-order scientific leverage: foundational senescence and senolytics publications became highly cited and were followed by numerous preclinical studies, early-phase human trials, and research spanning multiple diseases and institutions. This supports major field-building influence, although the evidence does not directly establish comparable effects on company formation, capital, policy, or public legitimacy.","confidence":"medium","n_a_reason":null},{"dimension":"strategic_taste","score":8.5,"rationale_summary":"Kirkland's record shows an unusually coherent and early strategic thesis: establish cellular senescence as a causal, druggable mechanism of age-related dysfunction, identify senolytics, validate them across disease models, and move them into humans. The progression from senescent-cell clearance in 2011 to senolytic discovery in 2015 and preliminary human studies in 2019 plausibly opened a major translational path for geroscience. A top-band score is withheld because the supplied evidence does not isolate his individual decision-making, demonstrate how contrarian the original choices were, or establish the counterfactual dependence of the field on his involvement.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension is applicable, but the supplied evidence demonstrates scientific impact and clinical translation rather than public risk-taking or conviction under adversity. No evidence establishes a contrarian public stance, career sacrifice, a personally consequential bet, persistence through serious criticism, or self-experimentation.","confidence":"high","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/james-l-kirkland"},{"public_id":"steve-horvath","name":"Steve Horvath","tagline":null,"photo_url":"/api/investor-photos/fc88c1bd-b031-4279-8074-3b8c170f5953.jpg","photo_checked_at":"2026-05-27 14:15:01.379171+00","primary_role":"scientist","roles":["scientist","populariser","philanthropist"],"role_tags":["scientist","populariser","philanthropist","investor"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Horvath made aging measurable enough for others to argue with it. His epigenetic clocks became a test bed for longevity claims, including studies that find no rejuvenation when the hype fails.","overall_score":40,"total_capital_moved":0,"updated_at":"2026-06-13 00:03:17.070097+00","scores":[{"dimension":"field_creation","score":7,"rationale_summary":"Steve Horvath appears to have materially created a new, legible longevity measurement category through the Horvath epigenetic clock, with independent academic evidence showing later researchers using 'Horvath's Clock' as a known biological-age test and applying CpG sites published by him. He also co-founded an Epigenetic Clock Development Foundation, but the evidence for organizational field-building is thin and partly uncorroborated. The strongest field_creation signal is category/protocol creation around epigenetic clocks rather than active institution-building or funding-path creation.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":8,"rationale_summary":"Horvath shows strong second-order leverage through field-spanning scientific uptake of epigenetic clocks and related methods: very high citation metrics, multiple foundational works with thousands of citations, a dedicated Epigenetic Clock Development Foundation, and recent follow-on applications across clinical biomarkers, sports performance, plasmapheresis trials, Alzheimer's biomarkers, and non-human species aging. Evidence supports major collaborator and follow-on-project leverage, though not broad capital, policy, founder, or public-legitimacy leverage.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":10,"rationale_summary":"Citation-weighted evidence is field-defining: OpenAlex reports an h-index of 151, nearly 140,000 total citations, and multiple foundational, heavily cited works including WGCNA and the multi-tissue DNA methylation age clock. The evidence supports major direct scientific influence on computational biology, epigenetic aging biomarkers, and the technical agenda of longevity research.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":7,"rationale_summary":"Horvath shows strong strategic taste around making aging measurable: the evidence supports a coherent, counterfactually important focus on epigenetic clocks and biomarker infrastructure, including development of the foundational Horvath clock and later foundation-building around epigenetic clock development. However, the record provided lacks direct evidence of an explicit strategy thesis, risk appetite, early contrarian reasoning, investment/deployment choices, or broader bet pattern beyond aging measurement.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":5,"rationale_summary":"The evidence supports that Horvath has a durable research vision centered on epigenetic clocks as biomarkers for measuring, validating, and guiding interventions that may extend healthspan and modulate biological aging. It also shows public alignment with immune/thymus rejuvenation as a possible aging-intervention pathway. However, the provided evidence does not show a broad, concrete, personally articulated end-state for ending aging or materially extending human lifespan, nor a detailed timeline or deployment roadmap. This is credible but more tool-and-pathway focused than field-defining future vision.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":1,"rationale_summary":"The dimension is applicable because Horvath has some institution-building signal through a reported role as co-founder and scientific advisory board chair of an epigenetic clock foundation, but the provided evidence contains no disclosed personal capital deployment, investments, donations, fund allocation, or quantified philanthropic support directed toward longevity. His scientific impact is strong, but that does not substantiate capital_deployed.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":2,"rationale_summary":"The dimension applies because Horvath is a public longevity/aging scientist, but the provided evidence contains almost no direct evidence of public risk-taking, personal downside, contrarian advocacy, sustained criticism, or self-experimentation. His epigenetic clock work is highly influential, but scientific impact alone is not bravery/conviction under this rubric.","confidence":"low","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/steve-horvath"},{"public_id":"vera-gorbunova","name":"Vera Gorbunova","tagline":"Biologist discovering natural mechanisms of cancer resistance and longevity","photo_url":"/api/investor-photos/bbbb04ca-6dfc-41a0-b965-2838a742dc6f.jpg","photo_checked_at":"2026-09-04 19:30:10.222189+00","primary_role":"scientist","roles":["scientist","populariser"],"role_tags":["scientist","populariser"],"theme_tags":["destination","path"],"impact_statement":"Gorbunova used long-lived mammals as natural experiments, helping identify links between naked-mole-rat cancer resistance, SIRT6-driven DNA repair, genome stability and longevity.","overall_score":39.67,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":8,"rationale_summary":"Gorbunova presents an ambitious and relatively concrete vision of translating longevity biology into therapies that restore whole-body function and extend healthy lifespan. Multiple roadmap and research-building activities demonstrate durable commitment, although the evidence lacks a defined development timeline and clear proof that every quoted roadmap statement reflects her individual position.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The evidence documents substantial scientific activity but identifies no investments, donations, or other capital deployments attributable to Vera Gorbunova. Scientific publications and citations are not evidence of capital deployed, so this dimension is inapplicable on the supplied record.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced for this research-focused scientist."},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Gorbunova demonstrates substantial field-building leverage through co-founding an aging-research center and producing research that has influenced a large body of subsequent work. Independent bibliometrics corroborate unusually broad scholarly reach, while major multi-institutional collaborations show network effects beyond her laboratory. However, the evidence does not establish the center's scale, talent-development outcomes, capital attracted, policy influence, or downstream ventures.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9,"rationale_summary":"Field-defining scientific influence is strongly supported by an h-index of 82, more than 27,000 citations, and several heavily cited foundational papers on transposable elements, cellular senescence, DNA repair, SIRT6, and naked-mole-rat cancer resistance. These metrics and topic-relevant landmark works demonstrate impact well beyond publication volume.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":7,"rationale_summary":"Gorbunova demonstrates a coherent and scientifically productive strategy: treating exceptionally long-lived mammals as natural experiments for identifying mechanisms of genome stability, cancer resistance, and longevity. The influential naked mole-rat hyaluronan and SIRT6/DNA-repair work suggests that this thesis opened valuable research paths. However, the evidence does not establish when these bets were made, how contrarian they were at inception, or a strong counterfactual showing that the field would have missed these paths without her.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":0,"rationale_summary":"The dimension applies, but the supplied evidence establishes scientific productivity and impact rather than public risk-taking or conviction. No evidence demonstrates a contrarian stance, career sacrifice, a consequential personal bet, persistence under serious criticism, or self-experimentation.","confidence":"high","n_a_reason":null},{"dimension":"field_creation","score":3,"rationale_summary":"Gorbunova is credited as co-founder of the Rochester Aging Research Center, a community intended to coordinate basic and translational aging researchers. This is relevant field-building, but the supplied sources do not independently attest the center's existence, activity, reach, durability, or outcomes, and the structured facts list it as inactive. The academic papers demonstrate scientific participation rather than creation of field infrastructure.","confidence":"low","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/vera-gorbunova"},{"public_id":"matt-kaeberlein","name":"Matt Kaeberlein","tagline":null,"photo_url":"/api/investor-photos/aa86a603-583e-4b6c-b0c9-377ec450cabb.jpg","photo_checked_at":"2026-05-27 14:15:03.166037+00","primary_role":"scientist","roles":["scientist","populariser","entrepreneur"],"role_tags":["scientist","populariser","entrepreneur"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Kaeberlein helped make mTOR, sirtuins, and rapamycin unavoidable in serious aging biology. Not a miracle salesman: his dog rapamycin trial found tolerability, not cardiac magic.","overall_score":39,"total_capital_moved":0,"updated_at":"2026-06-13 00:03:21.343008+00","scores":[{"dimension":"field_creation","score":5,"rationale_summary":"Field creation applies because the evidence attributes two longevity-relevant organization/program roles to Kaeberlein, including co-founding Ora Biomedical and serving as first director of the Dog Aging Project. However, the structured facts say neither organization is active, and the independent sources provided mainly show scientific participation rather than corroborating the specific field-building achievements or their downstream impact. Under the independence gate, the score should not exceed 5 without primary or independent corroboration of those organization-building claims.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"Evidence supports meaningful second-order leverage through organization-building and broad scientific influence: Kaeberlein founded or led two longevity-relevant organizations/projects and has very high citation reach, suggesting his work has helped mobilize collaborators and follow-on research. However, the evidence is thin on concrete downstream outcomes such as capital attracted, policy influence, startup creation by others, major public legitimacy effects, or documented talent pipelines, so this is not field-defining on the provided record.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9,"rationale_summary":"Primary citation metrics show very strong, field-shaping scientific impact in aging biology. An h-index of 81, 33,489 total citations, and multiple highly cited papers on Sir2/sirtuins, TOR/mTOR signaling, calorie restriction, and yeast lifespan indicate influence on core technical agendas in longevity research, not merely high publication volume.","confidence":"high","n_a_reason":null},{"dimension":"future_vision","score":8,"rationale_summary":"Kaeberlein has articulated a clear and durable future vision centered on targeting aging as a core preventive-medicine strategy, paired with concrete translational paths: systematic longevity-intervention screening, explicit large-scale discovery goals, and randomized trials of rapamycin in companion dogs. The evidence is unusually specific for this dimension, though it is framed more as geroscience and healthspan/lifespan extension than as an explicit promise to end aging outright.","confidence":"high","n_a_reason":null},{"dimension":"bravery_conviction","score":4,"rationale_summary":"There is credible but limited evidence of public conviction: Kaeberlein attached his name to off-label rapamycin healthspan research and to an ambitious million-intervention longevity testing proposal. This supports moderate bravery through controversial-position and big-bet flavors, but the evidence does not show major personal downside, sustained criticism, career sacrifice, or self-experimentation, so it falls well short of field-defining bravery.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":2,"rationale_summary":"The evidence shows longevity-focused institution-building roles, but no disclosed personal investments, donations, fund allocations, or concrete capital amounts attributable to Kaeberlein. Because capital deployment appears relevant through Optispan/Ora/LongeVC roles, this is not N/A, but the actual deployed-capital evidence is very thin.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":5,"rationale_summary":"Strategic taste applies, but the provided evidence supports only moderate strategic signal. Kaeberlein appears to have made coherent organization-building bets around aging biology, translational geroscience, dog aging, and rapamycin/mTOR-adjacent healthspan work. Founding/directing major longevity initiatives suggests field-building judgment, but the evidence does not show a clearly articulated thesis, early contrarian positioning, counterfactual importance, capital allocation record, or documented rationale strong enough for a high score.","confidence":"low","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/matt-kaeberlein"},{"public_id":"andrea-maier","name":"Andrea Maier","tagline":"Physician-scientist advancing precision geromedicine and healthy longevity","photo_url":"/api/investor-photos/87e50692-c96a-4456-8638-223d44d71099.jpg","photo_checked_at":"2026-09-04 20:03:12.453703+00","primary_role":"scientist","roles":["scientist","clinician","entrepreneur"],"role_tags":["scientist","clinician","entrepreneur"],"theme_tags":["destination","meta_view","path"],"impact_statement":"Andrea Maier has pushed geroscience toward clinical use through influential research on cellular senescence, sarcopenia and aging biomarkers. Her 747 papers have drawn 32,898 citations, with an h-index of 83.","overall_score":38.5,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":7,"rationale_summary":"Maier articulates a coherent and durable vision of precision geromedicine: measuring individualized aging trajectories and translating aging biology into targeted, evidence-based interventions that improve health across the lifespan. The vision includes concrete diagnostic, research, and clinical pathways, but stops short of a specific goal or timeline for ending aging, reversing decline, or radically extending human lifespan.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9,"rationale_summary":"Primary bibliometric evidence demonstrates exceptional and sustained scientific influence in geroscience. An h-index of 83 and 32,898 citations, combined with several heavily cited papers on cellular senescence, sarcopenia, aging biomarkers, and heterogeneous organ aging, indicate major influence on the field's technical and clinical agenda.","confidence":"high","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The supplied record establishes substantial scientific activity but no capital-deployment activity to evaluate. The structured facts identify zero investments, zero donations, and no catalytic positions or independently rated investees; scientific publications and citations do not substitute for deployed-capital outcomes.","confidence":"high","n_a_reason":"No public investment, donation, or other capital-deployment activity is evidenced for this physician-scientist."},{"dimension":"strategic_taste","score":4,"rationale_summary":"Maier shows a coherent strategy of translating geroscience into precision clinical interventions, with research spanning aging biomarkers, heterogeneous aging, and deeply phenotyped Asian cohorts. Co-founding Chi Longevity suggests an applied translational bet. However, the evidence does not establish that these choices were unusually early, contrarian, catalytic, or counterfactually important, so the demonstrated strategic taste remains moderate rather than field-defining.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":6,"rationale_summary":"Maier has credible field-building impact through co-founding the NUS Academy for Healthy Longevity and Chi Longevity, creating academic and clinical infrastructure for geromedicine. Independent academic sources corroborate the Academy's existence and active research role, but the evidence does not establish field-defining scale, broad community influence, or new funding paths.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":0,"rationale_summary":"The dimension applies, but the supplied evidence does not document public risk-taking or conviction in any rubric-defined form. Andrea Maier's substantial academic output and leadership establish scientific prominence, not bravery by this rubric.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Maier demonstrates substantial field-level leverage through a highly cited research portfolio, broad international collaborations, consensus work, and institution-building around healthy longevity. These signals indicate that her work enables follow-on research and convenes collaborators beyond her direct clinical and scientific output, although the evidence does not establish field-defining influence on capital, talent recruitment, or policy adoption.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/andrea-maier"},{"public_id":"leonard-guarente","name":"Leonard Guarente","tagline":"MIT aging researcher whose lab helped establish sirtuins and metabolic regulation as major longevity mechanisms; founder of Elysium Health.","photo_url":"/api/investor-photos/c7f70a8b-8e65-4177-9a9b-d4636d2b2ea7.png","photo_checked_at":"2026-06-15 21:00:02.202055+00","primary_role":"scientist","roles":["scientist"],"role_tags":["scientist"],"theme_tags":["destination","meta_view","path","risk_view"],"impact_statement":"Guarente helped make sirtuins and NAD biology unavoidable in longevity research: 71,187 citations, h-index 117, and landmark Sir2/SIRT papers. The consumer-translation case is thinner.","overall_score":38.5,"total_capital_moved":0,"updated_at":"2026-06-25 19:45:13.665448+00","scores":[{"dimension":"future_vision","score":6.5,"rationale_summary":"Guarente has a clear and durable longevity vision centered on extending healthy lifespan by targeting aging mechanisms, especially NAD/sirtuin/metabolic pathways, and translating them into interventions. The evidence supports ambition and scientific specificity, but it is less strong on a concrete public roadmap, timelines, or a broad field-defining vision for ending aging or full rejuvenation.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":2,"rationale_summary":"There is limited evidence of longevity-oriented institution-building through Elysium Health, but no disclosed personal investments, donations, fund allocations, or capital amounts. The available evidence supports involvement as a founder/scientific leader rather than demonstrated deployment of his own or controlled capital.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":7,"rationale_summary":"Guarente shows above-average strategic taste through a coherent, mechanism-led longevity thesis: sirtuins, NAD metabolism, metabolic regulation, and calorie-restriction biology as routes to aging intervention. The evidence supports an early and concentrated research-to-translation strategy, especially via Elysium Health, but does not establish detailed counterfactual importance, timing of bets, or broad capital-allocation judgment. This is strong for thesis coherence and field-relevant translation, weaker for documented contrarianism or measurable deployment impact.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":2,"rationale_summary":"The dimension applies, but the supplied evidence provides only weak, mostly self-published indications of field-building. Elysium-related sources suggest Guarente had a leadership/co-founder/founder role in a longevity company, which could count as creating an organization that made longevity products or research more public-facing, but the structured facts say no founded organizations were found and there is no independent or primary corroboration in the evidence set. His MIT lab's role in sirtuins is relevant to scientific impact, but it is not enough here to show creation of organizations, programs, communities, protocols, or funding paths.","confidence":"low","n_a_reason":null},{"dimension":"scientific_impact","score":9,"rationale_summary":"Citation metrics are the primary signal for this dimension, and the OpenAlex data show field-defining scientific influence: h-index 117, 71,187 citations, and multiple foundational Sir2/SIRT1/NAD/longevity papers with roughly 1,500-3,500 citations each. The most-cited works directly align with major longevity mechanisms, including sirtuins, NAD-dependent deacetylation, calorie restriction, yeast aging, C. elegans lifespan extension, and mammalian SIRT biology. This supports a very high scientific-impact score, though not a perfect 10 because the provided evidence does not include independent synthesis explicitly crediting him with founding or transforming the field beyond citation weight.","confidence":"high","n_a_reason":null},{"dimension":"bravery_conviction","score":5,"rationale_summary":"Guarente has moderate evidence of bravery/conviction: he publicly defended sirtuins and NAD-related longevity work amid controversy and uncertainty, and published at least one result that challenged an existing view about rapamycin mimicking calorie restriction. However, the evidence mostly shows scientific disagreement and public defense within normal academic/commercial discourse, not major career sacrifice, exceptional personal risk, or self-experimentation.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Guarente shows strong second-order scientific leverage through very high citation impact and heavily cited sirtuin/NAD/longevity papers that appear to have helped create substantial follow-on research activity. The evidence supports field-building within academic aging biology more clearly than capital, policy, founder, or public-movement leverage.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/leonard-guarente"},{"public_id":"laura-deming","name":"Laura Deming","tagline":"Founded The Longevity Fund as an early dedicated VC vehicle for aging and life-extension companies, helping make longevity biotech a fundable startup category.","photo_url":"/api/investor-photos/c1f4f19e-e998-4d96-ac63-139eed4ddd4c.jpg","photo_checked_at":"2026-06-12 23:00:04.193164+00","primary_role":"investor","roles":["investor","entrepreneur","populariser"],"role_tags":["investor","entrepreneur","populariser"],"theme_tags":["destination","meta_view","path","timeline"],"impact_statement":"Deming helped drag longevity biotech from weird sidebar into fundable company-building, then put her current bet on reversible organ cryopreservation. Not proof of victory; proof of taste.","overall_score":38,"total_capital_moved":0,"updated_at":"2026-06-13 00:03:29.916185+00","scores":[{"dimension":"capital_deployed","score":5,"rationale_summary":"The dimension applies because Deming is described as a longevity-focused venture capitalist who founded and ran The Longevity Fund, an early dedicated longevity VC vehicle. That is directly relevant institution-building and capital allocation, and her tagline suggests catalytic category-building. However, the provided evidence contains no disclosed investment count, fund size, portfolio names, personal capital at risk, or independently corroborated deployment amounts. The only concrete recent funding figure concerns Until Labs raising capital from others, not Deming deploying capital. Under the independence gate, the strong capital-deployment claim is supported mainly by an unknown-source dossier and self-published/promotional material, so the score should not exceed 5.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":6,"rationale_summary":"Field creation applies directly: the evidence identifies Deming as founder of The Longevity Fund, described as an early longevity-focused VC vehicle, plus later founder roles at Loyal and Until Labs. That supports meaningful creation of funding and company-building paths for longevity work. However, the strongest category-creation claim is mainly from structured facts and an unknown-independence dossier, while independent or primary corroboration of broad field-level impact is limited in the provided evidence, so the score should not be field-defining.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":6,"rationale_summary":"Bravery/conviction applies. The evidence shows Laura Deming publicly attaching her name and credibility to reversible cryopreservation and an explicit roadmap toward whole-body cryo, a position outside mainstream medical consensus. This supports contrarian public stance and some public-risk conviction, but the evidence is mostly self-published, recent, and does not document major personal downside, sustained criticism, or direct self-experimentation risk.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":7,"rationale_summary":"Deming has articulated a concrete and ambitious future vision around reversible cryopreservation as a staged path from organ preservation to whole-body cryo or hibernation-like medicine. The evidence is unusually specific for a future_vision dimension because it includes a roadmap, near-term commercial/medical use case, and longer-term endpoint. However, the record provided is narrow, mostly self-published, and lacks broader destination statements explicitly about ending aging or extending healthy lifespan beyond the cryopreservation pathway.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":1,"rationale_summary":"Primary citation evidence shows essentially no direct scientific publication impact: h-index 0, i10-index 0, 0 citations, and only one indexed work. The remaining evidence points mainly to investing, public interests, and self-published claims about cryopreservation work, but does not independently establish field-shaping scientific results.","confidence":"medium","n_a_reason":null},{"dimension":"strategic_taste","score":8,"rationale_summary":"Deming shows strong strategic taste evidence: a coherent, early, high-risk thesis around making longevity biotech fundable, first through The Longevity Fund and later through Until Labs. The Until strategy is especially thesis-coherent because it stages a speculative whole-body cryopreservation ambition through a nearer-term organ-preservation business case. Confidence is limited because most evidence is self-published and the record lacks disclosed investment portfolio details, outcomes, or independent validation of counterfactual importance.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":5,"rationale_summary":"The dimension applies: Deming's work is explicitly about creating and financing longevity companies, and the evidence supports some multiplier effect through founding multiple organizations and public recruiting/capital-formation activity. However, the strongest claims about field-level leverage, major capital attraction, and making longevity biotech fundable are supported mainly by self-published, promotional, or unknown-independence evidence, so the independence gate caps the score at 5.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/laura-deming"},{"public_id":"manuel-serrano","name":"Manuel Serrano","tagline":"Cell biologist translating senescence and reprogramming into regenerative medicine","photo_url":"/api/investor-photos/684f5610-0cdb-4a9b-b88a-e9dcab269df1.jpg","photo_checked_at":"2026-09-11 20:15:02.025448+00","primary_role":"scientist","roles":["scientist"],"role_tags":["scientist"],"theme_tags":["destination","path"],"impact_statement":"Serrano helped define the Hallmarks of Aging and mapped intermediate states of cellular reprogramming that may guide tissue regeneration and rejuvenation.","overall_score":37.33,"total_capital_moved":0,"updated_at":"2026-09-11 20:15:02.025448+00","scores":[{"dimension":"future_vision","score":6.5,"rationale_summary":"Serrano presents a durable and scientifically grounded vision of understanding and treating aging through cellular senescence, reprogramming, and tissue rejuvenation. He identifies several plausible intervention paths, including mitochondrial targeting, immune modulation, iron metabolism, and intermediate reprogramming states relevant to regeneration. However, the evidence does not establish a concrete human-development roadmap, timeline, or explicit commitment to ending aging or substantially extending healthy human lifespan.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The supplied evidence establishes substantial scientific activity, but capital_deployed evaluates outcomes produced by investments or donations. No such deployment is documented, so this dimension is inapplicable rather than merely weak.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced for Serrano; the record shows zero investments and zero donations."},{"dimension":"field_creation","score":1,"rationale_summary":"The dimension is applicable, but the supplied evidence shows scientific contributions rather than creation of organizations, programs, communities, protocols, categories, or funding paths that enabled others' longevity work.","confidence":"high","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Serrano has generated substantial second-order scholarly leverage: his highly cited work, especially the Hallmarks of Aging framework and foundational senescence research, has helped organize research agendas and enable extensive follow-on work across aging, cancer, and regenerative biology. However, the evidence does not establish comparable leverage through organization-building, capital deployment, policy influence, or founder creation.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9.5,"rationale_summary":"Serrano demonstrates field-defining scientific influence in cellular senescence and aging biology. His h-index of 99, nearly 80,000 citations, and multiple foundational papers with thousands of citations substantially exceed evidence of merely high publication volume. His work has shaped both the conceptual aging framework and the technical agenda around oncogene-induced senescence, tumor suppression, and cellular reprogramming.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":7,"rationale_summary":"Serrano demonstrates a coherent, decades-long scientific thesis linking cellular senescence, tissue plasticity, and reprogramming to aging, regeneration, and disease. His early work on oncogene-induced senescence and subsequent expansion into developmental senescence, cancer immunity, and in vivo reprogramming suggest strong selection of consequential research directions. However, the evidence does not establish explicit contemporaneous contrarian reasoning, uniquely catalytic choices, or a clear counterfactual showing that these paths would have remained closed without him.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension is applicable, but the supplied evidence demonstrates scientific productivity and exploration rather than public risk-taking or costly conviction. No evidence documents a contrarian public stance, career or financial sacrifice, a personally consequential bet, persistence under serious criticism, or self-experimentation.","confidence":"high","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/manuel-serrano"},{"public_id":"jamie-justice","name":"Jamie Justice","tagline":"Clinical geroscientist accelerating trials that target biological aging","photo_url":"/api/investor-photos/bb1ce0d2-7a92-457c-b9f6-5cb602e29c42.jpg","photo_checked_at":"2026-09-11 19:45:08.283283+00","primary_role":"scientist","roles":["scientist","operator","populariser"],"role_tags":["scientist","operator","populariser"],"theme_tags":["destination","meta_view","path"],"impact_statement":"Jamie Justice helped move geroscience toward human trials through a first-in-human senolytics study and widely cited frameworks for selecting and validating aging biomarkers.","overall_score":36.75,"total_capital_moved":0,"updated_at":"2026-09-11 19:45:08.283283+00","scores":[{"dimension":"future_vision","score":7,"rationale_summary":"Justice articulates a durable, clinically oriented vision of extending healthspan by targeting the biology of aging, restoring function, and translating validated biomarkers into geroscience trials. The vision is ambitious and supported by a concrete translational pathway and an international competition, but it stops short of a detailed timeline, comprehensive theory of aging, or explicit commitment to ending aging or radically extending lifespan.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The dimension is inapplicable on the supplied evidence. There are no identified investments, donations, rated investees, catalytic positions, or capital-backed longevity outcomes attributable to Justice. Her publications and XPRIZE role demonstrate geroscience activity but do not establish personal or directed capital deployment.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced for Jamie Justice; the record reflects scientific and programmatic work rather than investing or donating."},{"dimension":"scientific_impact","score":8.5,"rationale_summary":"Strong, independently corroborated scientific influence in geroscience. Citation-weighted evidence shows substantial field uptake, including a highly cited first-in-human senolytics study and several influential biomarker and physiological-geroscience papers. The record is highly impactful, though not sufficient to establish singular, field-defining leadership at the very highest tier.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":3,"rationale_summary":"Justice’s work shows a coherent translational emphasis on biomarkers and human geroscience trials, including participation in an early first-in-human senolytics study and efforts to define biomarker standards. However, the evidence does not establish that she personally originated these bets, pursued them contrarianly, or made counterfactually important strategic allocation decisions.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":6,"rationale_summary":"Justice has credible field-building impact through leadership of translational clinical-trial networks, an NIA-supported geroscience training network, and XPRIZE Healthspan, a global competition that provides a visible framework and incentive structure for longevity interventions. The evidence supports substantial program and network leadership, but not founding an organization or independently documented field-defining outcomes.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"Justice demonstrates substantial scholarly multiplier effects: her geroscience and biomarker research has attracted thousands of citations and contributed to collaborative frameworks, workshops, and consortia that can shape subsequent research and clinical-trial design. However, the evidence does not establish comparable leverage in attracting capital, founders, policy action, or institution-building.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension is applicable, but the supplied evidence does not document any qualifying public risk-taking or conviction. Justice's leadership of a global healthspan competition and substantial geroscience research record show commitment to the field, but they do not establish contrarian advocacy, career sacrifice, a capacity-relative bet, persistence under serious criticism, or personal risk.","confidence":"high","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/jamie-justice"},{"public_id":"maria-blasco","name":"Maria Blasco","tagline":"Telomere biologist investigating aging and cancer","photo_url":"/api/investor-photos/6a303b9f-61b0-440c-ba3f-ac8d34c1f9e5.jpg","photo_checked_at":"2026-09-04 20:03:19.831521+00","primary_role":"scientist","roles":["scientist","operator"],"role_tags":["scientist","operator"],"theme_tags":["meta_view","path"],"impact_statement":"Blasco helped shape modern telomere biology. Her 508 papers have drawn more than 71,000 citations, including foundational work linking telomerase loss, aging, and cancer.","overall_score":36.75,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":6,"rationale_summary":"Blasco presents a durable and scientifically specific vision centered on targeting telomeres and telomerase to treat age-related disease and promote healthy aging. Proposed routes include telomerase gene therapy, telomerase reactivation for fibrosis, and young small-extracellular-vesicle treatment. However, the evidence does not show a clearly articulated destination for ending aging or materially extending human lifespan, nor timelines, clinical milestones, or sustained public advocacy for such an overarching goal.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension is applicable, but the supplied evidence documents scientific productivity and recognition rather than public risk-taking or conviction. No evidence establishes a contrarian stance, career sacrifice, a personally significant bet, persistence under serious criticism, or self-experimentation.","confidence":"high","n_a_reason":null},{"dimension":"scientific_impact","score":9.5,"rationale_summary":"Exceptional citation-weighted impact indicates field-defining influence in aging and telomere biology. An h-index of 117, more than 71,000 citations, and multiple foundational papers exceeding 1,000 citations demonstrate influence far beyond publication volume.","confidence":"high","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Blasco demonstrates substantial scholarly multiplier effects: a large, highly cited body of work has influenced aging and telomere research well beyond her direct experiments, while multi-institutional publications indicate broad collaboration. However, the evidence does not establish comparable leverage through organization-building, capital deployment, policy influence, or founder formation.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The supplied evidence documents substantial scientific activity but no deployment of investment or philanthropic capital. Scientific publications, citations, and awards do not make the capital_deployed dimension applicable.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced; Maria Blasco is presented as a scientist, with zero investments or donations found."},{"dimension":"strategic_taste","score":6,"rationale_summary":"Blasco’s sustained focus on telomeres and telomerase represents a coherent scientific thesis connecting aging, cancer, and regenerative capacity. Her highly cited mouse studies from the late 1990s suggest an early, productive commitment to this research direction. However, the evidence does not establish that these choices were contrarian, uniquely catalytic, or counterfactually decisive for the field, so a top-tier score is not justified.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":2,"rationale_summary":"Blasco contributed to field-building by locally organizing an international healthy-aging conference, but the evidence does not show that she created a new organization, program, category, community, protocol, or funding pathway.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/maria-blasco"},{"public_id":"juan-carlos-izpisua-belmonte","name":"Juan Carlos Izpisua Belmonte","tagline":null,"photo_url":"/api/investor-photos/9859ae3b-cdcd-464e-aeab-d69e52a6eed6.png","photo_checked_at":"2026-05-20 14:00:00.585105+00","primary_role":"scientist","roles":["scientist","entrepreneur"],"role_tags":["scientist","entrepreneur"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Belmonte made cellular reprogramming a serious aging target, not a wellness slogan. His record includes 54,692 citations and major work on partial reprogramming of age-associated hallmarks.","overall_score":36,"total_capital_moved":0,"updated_at":"2026-06-13 00:03:34.168786+00","scores":[{"dimension":"strategic_taste","score":5,"rationale_summary":"The evidence supports a coherent strategic orientation around cellular reprogramming, regeneration, and aging biology, culminating in a founding scientist/SVP role at Altos Labs. This suggests a meaningful longevity-relevant bet on programming cells toward healthier earlier-life states. However, the record does not provide explicit thesis formation, timing, rationale, capital allocation, counterfactual importance, or evidence that he chose paths others were missing, so the strategic-taste score should be moderate with limited confidence.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"Belmonte has credible multiplier-effect evidence through founding Altos Labs and producing highly cited work that appears to have generated substantial follow-on scholarly activity in reprogramming, regeneration, genome editing, and aging biology. However, the supplied evidence is stronger for academic influence than for broader second-order leverage such as capital attraction, policy attention, founder creation, or documented talent recruitment.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9,"rationale_summary":"The primary citation-metrics evidence shows very high scientific influence: h-index 127, i10-index 395, 54,692 total citations, and multiple heavily cited papers across induced pluripotent stem cells, regeneration, genome editing, and partial reprogramming. The most-cited works include several foundational or agenda-setting papers near or above 1,000 citations, including work directly relevant to aging and rejuvenation biology. This supports a field-defining scientific impact score, though not a perfect score because the provided evidence does not show clinical translation or even higher citation concentration at the very top end.","confidence":"high","n_a_reason":null},{"dimension":"capital_deployed","score":2,"rationale_summary":"There is minimal evidence of capital deployment. The only relevant signal is that Belmonte is described as a Founding Scientist and Senior Vice President at Altos Labs, which may indicate some institution-building role in a longevity-focused company, but the evidence provides no disclosed personal capital, donations, investments, fund allocation authority, or quantified resources attributable to him.","confidence":"low","n_a_reason":null},{"dimension":"future_vision","score":7,"rationale_summary":"Belmonte has a clear and durable future-vision signal centered on partial cellular reprogramming, restoring youthful/healthier cell states, and developing regenerative interventions against age-related decline. The evidence is ambitious and mechanistically specific, with repeated statements linking reprogramming to improved health span, life span, resilience, and reversal of aging hallmarks. The score is not higher because the provided evidence contains no direct destination quote, explicit public timeline, or broad societal vision for ending aging in humans.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":5,"rationale_summary":"The evidence supports a plausible field-creation contribution through helping found or lead Altos Labs, a longevity-relevant company focused on cellular reprogramming. However, the direct founder claim is only weakly sourced here, and the primary/independent sources only corroborate his Altos affiliation, not that he created the organization or broader field infrastructure. This caps the score at 5 under the independence gate.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":2,"rationale_summary":"The dimension applies, but the provided evidence shows mainly professional commitment to cellular reprogramming and aging biology, not clear public risk-taking, sacrifice, contrarian advocacy, sustained criticism, or personal risk. His Altos Labs leadership role gives some visible conviction in an ambitious longevity-adjacent program, but the evidence does not establish bravery in the rubric sense.","confidence":"low","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/juan-carlos-izpisua-belmonte"},{"public_id":"anne-brunet","name":"Anne Brunet","tagline":"Geneticist uncovering the molecular mechanisms of longevity","photo_url":"/api/investor-photos/b68c133e-ac10-4031-a017-811ef2b7eeae.jpg","photo_checked_at":"2026-09-18 20:30:01.932828+00","primary_role":"scientist","roles":["scientist"],"role_tags":["scientist"],"theme_tags":["destination","meta_view","path"],"impact_statement":"Brunet helped establish FOXO and SIRT1 as central molecular links between stress responses and longevity. Her 253 papers have drawn more than 52,000 citations.","overall_score":35.58,"total_capital_moved":0,"updated_at":"2026-09-18 20:30:01.932828+00","scores":[{"dimension":"capital_deployed","score":null,"rationale_summary":"Anne Brunet is evidenced here as a longevity scientist, but there are no identified investments, donations, or capital-backed outcomes to evaluate. Her substantial scientific output does not constitute capital deployment under this rubric.","confidence":"high","n_a_reason":"No public investment or donation activity is evidenced, so capital deployment is inapplicable."},{"dimension":"future_vision","score":7,"rationale_summary":"Brunet articulates a durable, scientifically grounded vision of delaying and potentially reversing aspects of aging through epigenetic reprogramming, stem-cell rejuvenation, and targeted geroscience interventions. Her vision identifies concrete mechanisms and desired human-health outcomes, especially preventing cognitive decline and extending tissue healthspan. It falls short of a field-defining score because the evidence does not show a comprehensive roadmap, timeline, explicit commitment to ending aging, or a clearly unified public theory of radical human lifespan extension.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9.5,"rationale_summary":"Primary bibliometric evidence indicates field-defining scientific influence. Brunet has an h-index of 92 and 52,133 citations, with multiple foundational papers on Akt, FOXO, SIRT1, and geroscience receiving thousands of citations. Her continuing work spans core longevity mechanisms and emerging aging-research methods, although the evidence does not establish clinical translation.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":6,"rationale_summary":"Brunet shows a coherent scientific thesis around genetic and epigenetic control of longevity, including early work on FOXO/SIRT1 and a notable pursuit of controversial transgenerational epigenetic inheritance. These choices appear scientifically prescient and helped develop important aging-research paths, but the supplied evidence does not establish explicit thesis formation, unusual risk-taking, or a strong counterfactual case that her choices uniquely redirected the field.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":1,"rationale_summary":"The dimension applies, but the supplied evidence documents scientific research rather than creation of organizations, programs, communities, protocols, categories, or funding paths. The structured facts explicitly report no founded organizations or donation-created programs.","confidence":"high","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension applies, but the supplied evidence documents scientific productivity and longevity research rather than public risk-taking or conviction. No evidence demonstrates a contrarian stance, career sacrifice, a personally significant bet, persistence under serious criticism, or self-experimentation.","confidence":"high","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"Brunet demonstrates substantial academic multiplier effects through exceptionally high citation impact and collaborations spanning institutions and disciplines. This indicates that her research has enabled significant follow-on scholarship and attracted collaborators, although the evidence does not establish comparable leverage through organization-building, capital, policy, entrepreneurship, or public mobilization.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/anne-brunet"},{"public_id":"paul-d-robbins","name":"Paul D. Robbins","tagline":"Translational geroscientist developing senotherapeutics for healthier aging","photo_url":"/api/investor-photos/3231a7f4-24c8-4794-acf7-28de6e748965.jpg","photo_checked_at":"2026-09-04 19:30:07.446245+00","primary_role":"scientist","roles":["scientist"],"role_tags":["scientist"],"theme_tags":["path"],"impact_statement":"Robbins helped establish senolytics as a major longevity research path by identifying compounds that clear senescent cells and showing gains in physical function and lifespan.","overall_score":35.58,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":5,"rationale_summary":"Robbins presents a concrete and scientifically grounded strategy for extending healthspan through senotherapeutics targeting multiple hallmarks of aging. His influential, sustained research program supports the durability of this direction, but the evidence contains no explicit destination vision, human-lifespan objective, development timeline, or discussion of translational risks.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The evidence establishes Robbins's substantial scientific impact but identifies no investments, donations, or other deployment of personal or controlled capital. Scientific achievements alone do not make the capital_deployed dimension applicable.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced for this scientist."},{"dimension":"strategic_taste","score":7,"rationale_summary":"Robbins’s publication record shows a coherent translational bet on cellular senescence: defining the mechanism, identifying senolytic compounds, and demonstrating healthspan and lifespan effects. The highly cited 2015–2018 work suggests that this research direction helped establish senotherapeutics as a consequential longevity pathway. However, the evidence does not establish his individual decision-making role, the contemporaneous contrarian nature of the bet, or a clear counterfactual showing that the path depended on him.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":1,"rationale_summary":"Field creation is applicable, but the supplied evidence establishes scientific collaboration and protocol-relevant research rather than creation of organizations, programs, categories, communities, protocols, or funding paths. Robbins is affiliated with an aging institute, but no evidence shows that he founded it or created a field-building structure.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension applies, but the supplied evidence documents scientific productivity and mainstream institutional research rather than public risk-taking or conviction. No qualifying bravery exhibit, career sacrifice, contrarian stance, persistence under serious criticism, consequential personal bet, or self-experimentation is shown.","confidence":"high","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Robbins demonstrates substantial second-order scientific leverage: his highly cited senescence and senolytic research has influenced a large body of follow-on work, while extensive multi-institutional collaborations and participation in a regional geroscience consortium indicate field-building reach beyond his laboratory. Evidence for attracting capital, founding organizations, shaping policy, or generating companies is absent, limiting a higher score.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9.5,"rationale_summary":"Robbins demonstrates field-defining scientific influence, particularly in cellular senescence and senolytics. His exceptional citation profile is reinforced by several foundational geroscience papers with more than 1,000 citations each, showing influence well beyond publication volume.","confidence":"high","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/paul-d-robbins"},{"public_id":"vadim-gladyshev","name":"Vadim Gladyshev","tagline":"Redox biologist mapping the mechanisms and signatures of aging","photo_url":"/api/investor-photos/5b5054b5-6aa7-453e-a4bd-99194d221306.png","photo_checked_at":"2026-09-11 20:15:04.660407+00","primary_role":"scientist","roles":["scientist"],"role_tags":["scientist"],"theme_tags":["destination","meta_view","path","risk_view"],"impact_statement":"Gladyshev helped shape aging research across biological clocks, biomarkers, comparative longevity and epigenetic rejuvenation. His 790 papers have received more than 56,000 citations.","overall_score":35.47,"total_capital_moved":0,"updated_at":"2026-09-11 20:15:04.660407+00","scores":[{"dimension":"future_vision","score":8,"rationale_summary":"Gladyshev articulates an ambitious and technically concrete vision of radically extending lifespan and healthspan by identifying robust longevity and rejuvenation signatures, screening interventions against them, and combining precision diagnostics, damage-removal therapies, metabolic targets, and replacement strategies. His roadmap and explicit attention to biological-age reversal standards and intervention risks make the vision unusually rigorous, although the evidence lacks a defined human timeline or a single consistently stated end-state program.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension applies, but the supplied evidence documents scientific productivity rather than public risk-taking or conviction. Gladyshev’s extensive aging research shows sustained engagement with the field, yet none of the five specified bravery flavors is demonstrated.","confidence":"high","n_a_reason":null},{"dimension":"scientific_impact","score":9.4,"rationale_summary":"Primary bibliometric evidence indicates field-defining scientific influence across redox biology and aging: an h-index of 128, more than 56,000 citations, and numerous highly cited papers spanning selenoproteins, aging clocks, biomarkers, comparative longevity, and epigenetic rejuvenation. The breadth of foundational work and sustained influence on major aging-research agendas support a near-top score.","confidence":"high","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Gladyshev demonstrates substantial second-order scientific leverage through an exceptionally influential publication record and broad, cross-institutional collaborations that enable follow-on research beyond his laboratory. However, the evidence does not establish comparable leverage in organization-building, capital mobilization, policy, entrepreneurship, or public legitimacy.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The evidence establishes substantial scientific activity but provides no capital-deployment record to evaluate. Publications and citation impact are not substitutes for investment or donation outcomes under this dimension.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced for this scientist: no investments or donations were found."},{"dimension":"strategic_taste","score":4,"rationale_summary":"Gladyshev’s work shows a coherent strategy spanning comparative longevity, molecular aging signatures, biomarkers, resilience, and interventions. This suggests sound scientific taste, but the evidence does not establish that he originated unusually early or contrarian theses, led the cited projects, or made choices that were counterfactually important to the field.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":1,"rationale_summary":"The dimension is applicable, but the supplied evidence shows scientific collaboration and platform development rather than creation of organizations, programs, communities, protocols, categories, or funding paths that enabled the broader longevity field. The structured facts explicitly report no founded organizations or donation-created programs.","confidence":"high","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/vadim-gladyshev"},{"public_id":"morgan-levine","name":"Morgan Levine","tagline":"Computational biologist building rigorous measures of biological aging","photo_url":"/api/investor-photos/5293bfe7-e09c-40f5-a3c8-41426dc2833a.jpg","photo_checked_at":"2026-09-04 19:30:11.508419+00","primary_role":"scientist","roles":["scientist","operator"],"role_tags":["scientist","operator"],"theme_tags":["meta_view","path"],"impact_statement":"Morgan Levine helped make biological aging measurable: her epigenetic clocks predict health and mortality risk, while her methods have shaped studies with more than 20,000 citations across her work.","overall_score":35.23,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":5,"rationale_summary":"Levine presents a credible, durable research vision in which validated biological-aging measures enable intervention testing and illuminate mechanisms such as epigenetic reprogramming. Her work aligns with the broader geroscience goal of extending healthspan, but the evidence does not show a personally articulated, field-defining destination, timeline, or comprehensive strategy for ending aging or reversing human decline.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The evidence establishes substantial scientific activity but no capital deployment to evaluate. Structured facts identify zero investments, zero donations, and no backed companies, catalytic positions, or independently rated outcomes; academic publications do not demonstrate deployment of capital.","confidence":"high","n_a_reason":"No public investment, donation, or other capital-deployment activity is evidenced for Morgan Levine."},{"dimension":"field_creation","score":3,"rationale_summary":"Levine co-developed a broadly applicable computational protocol that substantially improved the reliability of epigenetic clocks, potentially making aging measurements more usable in longitudinal studies and clinical trials. This is a credible enabling contribution, but the evidence does not demonstrate creation of an organization, program, community, funding path, or widely adopted field-defining standard.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Levine's aging-measurement research has substantial second-order scientific leverage: highly cited methods have been adopted across large, multi-institutional studies and applied beyond their original setting. This demonstrates strong collaborator attraction and follow-on research, though the evidence does not establish comparable leverage in organization-building, capital, policy, or founder creation.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9.2,"rationale_summary":"Primary bibliometric evidence indicates field-defining scientific influence, particularly in biological-age measurement and epigenetic clocks. A high h-index, more than 20,000 citations, and several papers exceeding 900 citations demonstrate sustained impact beyond publication volume.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":5,"rationale_summary":"Levine’s sustained, early focus on computational and epigenetic measures of biological aging shows a coherent research direction that became influential. However, the evidence does not establish how deliberately contrarian these choices were, whether they opened paths others overlooked, or whether Levine made counterfactually important allocation, founding, or deployment decisions.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension applies, but the supplied evidence shows scientific engagement with longevity rather than documented public risk-taking or conviction. Levine coauthored work advancing the once-nonmainstream geroscience premise that aging is malleable, but there is no evidence that she personally took a contrarian public stance, incurred career or financial downside, persisted through serious criticism, made a capacity-relative bet, or self-experimented.","confidence":"high","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/morgan-levine"},{"public_id":"eric-verdin","name":"Eric Verdin","tagline":null,"photo_url":"/api/investor-photos/f4bb23e8-5e0a-4d3c-958e-2dbe279ed16c.png","photo_checked_at":"2026-05-27 13:45:09.664257+00","primary_role":"scientist","roles":["scientist","entrepreneur","investor"],"role_tags":["scientist","entrepreneur","investor"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Verdin helped drag geroscience from aging folklore into citation-heavy biology: 73,392 citations, h-index 133, and major work on NAD+, sirtuins, inflammation, and aging biomarkers.","overall_score":35,"total_capital_moved":0,"updated_at":"2026-06-13 00:03:43.35065+00","scores":[{"dimension":"scientific_impact","score":9,"rationale_summary":"Eric Verdin has field-defining scientific impact by the rubric's primary signal: OpenAlex reports an h-index of 133, 73,392 total citations, and multiple highly cited works in aging-relevant mechanisms including inflammation, NAD+ biology, sirtuins, mitochondrial metabolism, acetylation, and beta-hydroxybutyrate. The citation profile shows broad and sustained influence beyond publication volume, with several works exceeding 1,000 citations. Recent primary publications also show continued agenda-setting involvement in translational geroscience and biomarkers of aging, though the evidence does not show clinical trials directly led by him.","confidence":"high","n_a_reason":null},{"dimension":"future_vision","score":8,"rationale_summary":"Verdin has articulated a durable and concrete geroscience vision centered on translating aging biology into personalized gerotherapeutics, biomarkers, clinical validation, and scalable interventions to extend healthy lifespan. The evidence shows ambition and specificity, while also preserving scientific caution around trials, dosing, safety, and variability. This is strong field-leadership evidence, though not quite maximal because much of it appears in coauthored academic or institutional contexts rather than a singular public manifesto explicitly claiming an end to aging.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":2,"rationale_summary":"The dimension is applicable because Verdin leads a major longevity-focused research institute, but the provided evidence contains no disclosed personal investments, donations, fund allocations, or quantified capital deployment. His President/CEO role at the Buck Institute suggests institution-building responsibility in longevity, but without evidence of capital personally deployed or resources he directly allocated, the score must remain low.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":3,"rationale_summary":"Strategic taste is applicable because Verdin is linked to company formation and ecosystem roles, but the provided evidence does not show a clear investment or company-building thesis, timing, contrarian rationale, stage preference, or counterfactual importance. His scientific and institutional focus in aging biology suggests broad field coherence, but the evidence is too thin to credit strong strategic judgment beyond modest participation in longevity translation.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":5,"rationale_summary":"Evidence supports some field-creation activity: Verdin is credited with founding three longevity-related companies and is associated with The Academy of Health & Lifespan Research, which appears aimed at advancing geroscience as a field. However, the company-founding evidence lacks detailed independent corroboration here, all listed companies are marked inactive, and the Academy source shows affiliation/authorship rather than clearly proving he created the organization or program.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension applies, but the provided evidence contains almost no direct indicators of public risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, or self-experimentation. Verdin is clearly a prominent geroscientist and institutional leader in aging research, but prominence and scientific output alone do not establish bravery/conviction under this rubric.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Eric Verdin shows substantial second-order leverage through founding three therapeutics companies, very high field citation reach, and participation in large cross-institutional consensus and translational longevity publications. The evidence supports broad scientific legitimacy, collaborators, and follow-on translational projects, but does not directly document capital attracted, policy influence, trainee/founder lineage, or investment/donation leverage.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/eric-verdin"},{"public_id":"guido-kroemer","name":"Guido Kroemer","tagline":"Cell biologist connecting metabolism, autophagy, and aging","photo_url":"/api/investor-photos/ec73fca2-3e86-4b41-b739-eb81ce7d9d39.jpg","photo_checked_at":"2026-09-04 20:03:15.70454+00","primary_role":"scientist","roles":["scientist"],"role_tags":["scientist"],"theme_tags":["path","risk_view"],"impact_statement":"Kroemer helped define how aging research understands autophagy, metabolism, and cell death. His 2,322 papers have drawn more than 383,000 citations.","overall_score":35,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":4,"rationale_summary":"Kroemer articulates several concrete, mechanistically grounded paths for improving healthspan and addressing age-related decline, especially through autophagy, stress resilience, gerodiagnostics, and precision geromedicine. However, the evidence does not show a clear overarching destination, timeline, or publicly consistent commitment to ending aging, reversing aging broadly, or materially extending human lifespan.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":10,"rationale_summary":"Exceptional citation-weighted evidence demonstrates field-defining scientific influence across aging, autophagy, cell death, metabolism, and cancer biology. The combination of an h-index of 286, 383,433 citations, and numerous foundational papers with thousands of citations warrants the maximum score.","confidence":"high","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The evidence establishes substantial scientific output but provides no capital-deployment activity to evaluate. Scientific publications and citations are not substitutes for investments or donations under this dimension.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced for this scientist: no investments or donations were found."},{"dimension":"strategic_taste","score":4,"rationale_summary":"Kroemer’s sustained work linking autophagy, metabolism, cell death, cancer, immunity, and aging suggests a coherent scientific thesis with major field influence. However, the supplied evidence does not establish that he selected these directions unusually early, against prevailing views, or with clear counterfactual importance. The record supports promising mechanistic and translational choices, but not a high-confidence account of strategic taste.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":1,"rationale_summary":"The dimension is applicable, but the supplied evidence shows scientific discoveries and ongoing research rather than creation of organizations, programs, communities, protocols, categories, or funding paths that enabled longevity work for others.","confidence":"high","n_a_reason":null},{"dimension":"bravery_conviction","score":3,"rationale_summary":"There is limited evidence of public contrarian conviction: Kroemer co-authored a paper advocating avoidance of widely used benzodiazepines in sepsis-heavy intensive-care populations. However, the record does not establish substantial personal risk, career sacrifice, sustained resistance to serious criticism, a large capacity-relative bet, or self-experimentation.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":8,"rationale_summary":"Exceptional citation reach and multiple highly cited field-shaping papers demonstrate substantial second-order leverage through knowledge diffusion, collaborator networks, and follow-on research. However, the evidence does not establish comparable leverage through organization-building, talent development, capital, policy, or public mobilization.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/guido-kroemer"},{"public_id":"michael-levin","name":"Michael Levin","tagline":"Regenerative biology and bioelectricity pioneer.","photo_url":"/api/investor-photos/4922e796-db65-4460-8564-bfaa2ffb7c06.jpg","photo_checked_at":"2026-05-15 11:57:19.764103+00","primary_role":"scientist","roles":["scientist","entrepreneur"],"role_tags":["scientist","entrepreneur"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Levin gave longevity a less fashionable but useful target: tissue-level bioelectric control. His work treats aging partly as failed morphostasis, not just a pile of broken genes.","overall_score":35,"total_capital_moved":0,"updated_at":"2026-06-13 00:03:38.777869+00","scores":[{"dimension":"future_vision","score":7,"rationale_summary":"Levin has a clear, durable vision linking bioelectric information, morphostasis, regeneration, and aging, with repeated statements about reading/editing bioelectric code and restoring tissue-level organization. The vision is ambitious and conceptually specific, but the provided evidence is stronger on scientific framework and regenerative direction than on a concrete public roadmap, timeline, or explicit claim to end aging or materially extend human lifespan.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":3,"rationale_summary":"The dimension applies, but the evidence for bravery/conviction is limited to one medium-strength contrarian signal: Levin publicly advanced a bioelectric framing of aging that was described as not yet integrated into mainstream aging research. This supports some public intellectual risk-taking, but there is no evidence here of career sacrifice, sustained criticism, unusually large personal bets, or self-experimentation.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":7,"rationale_summary":"The citation_metrics source reports very strong bibliometrics for a Michael Levin profile, with h-index 87, 38,373 citations, and 350 i10-index, which would normally indicate major scientific influence. However, the most-cited works listed are largely pediatric infectious disease/sepsis papers that do not match the regenerative biology/bioelectricity hero identity, so the citation signal appears partially contaminated or mismatched. Primary papers tied to planarian regeneration, bioelectric patterning, stem-cell electrical state, and aging support genuine scientific impact in the relevant field, but the evidence here does not cleanly show field-defining citation weight for those specific works.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":3,"rationale_summary":"The dimension applies, but the provided evidence only supports one explicit founding-related activity: co-founding Astonishing Labs, described as adjacent to longevity through regenerative medicine and synthetic bioengineering. There is no evidence here that the organization became active, created a durable field category, community, protocol, program, or funding path, and the independent sources provided do not corroborate this field-creation claim for the regenerative biology Michael Levin.","confidence":"low","n_a_reason":null},{"dimension":"capital_deployed","score":2,"rationale_summary":"There is limited evidence of institution-building activity relevant to regenerative biology, including directing Tufts centers and co-founding Astonishing Labs, but no evidence of personal capital deployment, disclosed funding amounts, donations, investments, or fund allocation. This supports only a low score for capital_deployed.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":7,"rationale_summary":"Levin shows strong thesis coherence around regenerative biology as programmable morphogenesis, using bioelectric and cognitive properties of cells/tissues as control systems rather than conventional single-target intervention. This is plausibly contrarian and strategically important for longevity-adjacent regeneration, but the evidence is mostly self-published and lacks dates, early-bet timing, counterfactual detail, funding/deployment history, or independent validation of field-opening impact.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"The evidence supports meaningful second-order leverage through a large publication/citation footprint, repeated collaborators, and influence on bioelectricity/regeneration framing, plus one founded organization. However, direct evidence for attracting capital, policy attention, major follow-on companies, or broad institutional ecosystem-building is sparse, and some citation-metric evidence appears contaminated by works likely belonging to a different Michael Levin, limiting confidence in a higher score.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/michael-levin"},{"public_id":"shinya-yamanaka","name":"Shinya Yamanaka","tagline":null,"photo_url":"/api/investor-photos/d1c1c118-5d55-4307-bf74-7aa55f124831.jpg","photo_checked_at":"2026-05-20 14:00:00.591172+00","primary_role":"scientist","roles":["scientist","operator"],"role_tags":["scientist","operator"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Yamanaka gave longevity science its sharpest cell-level reset button: iPS reprogramming. It lets researchers rewind adult cells, model disease, and test regenerative medicine; lifespan claims can wait.","overall_score":34.5,"total_capital_moved":0,"updated_at":"2026-06-13 00:03:48.355824+00","scores":[{"dimension":"field_creation","score":8,"rationale_summary":"Yamanaka has strong field-creation evidence through the creation of the iPSC/Yamanaka-factor reprogramming category and protocol, which independent sources describe as broadly enabling new models, regenerative medicine, drug discovery, and cellular aging research. However, the supplied evidence does not show founded organizations, donation-created programs, or funding paths.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":2,"rationale_summary":"The dimension applies, but the provided evidence contains almost no direct indicators of public risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, or personal skin in the game. Yamanaka's iPSC discovery was highly consequential and later Nobel-recognized, but scientific importance alone does not establish bravery_conviction under this rubric. A low score is warranted because there is some implicit research conviction in pioneering iPSC work, but the evidence supplied does not document public or personal risk.","confidence":"low","n_a_reason":null},{"dimension":"scientific_impact","score":6,"rationale_summary":"The dimension applies: the evidence shows primary academic authorship in embryonic stem cell and induced pluripotent stem cell biology, including work on developmental potency mapping, iPS-derived endothelial cells, and SIRT1 regulation during reprogramming. However, no citation metrics are provided, and the supplied papers do not include clear citation-weighted evidence of field-defining impact, so the score should not rely on Yamanaka's broader reputation.","confidence":"medium","n_a_reason":null},{"dimension":"strategic_taste","score":6.5,"rationale_summary":"Strategic taste applies because Yamanaka made a field-defining scientific choice around cellular reprogramming that opened major paths for regenerative medicine and aging-relevant research. The evidence supports strong counterfactual importance of the iPS/Yamanaka-factor work, but it does not document an explicit strategy thesis, early contrarian reasoning, funding bets, stage preference, or a broader pattern of thesis-driven deployment choices.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":4,"rationale_summary":"Yamanaka has a clear translational regenerative-medicine vision around iPS cells, including clinical applications, disease modeling, stem cell therapy, and potentially inexhaustible cell-derived products. However, the provided evidence does not show that he publicly articulated a concrete, durable vision specifically for ending aging, reversing organism-level biological decline, or materially extending healthy human lifespan. The aging connection is present mainly as a research application and mechanistic implication, not as a direct longevity vision.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":2,"rationale_summary":"There is limited evidence of institution-building involvement through leadership at CiRA/CiRA Foundation, but no disclosed investments, donations, personal capital deployment, fund allocation amounts, or independently corroborated catalytic funding activity. This supports only a low score for capital deployed, with low confidence.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"Yamanaka shows credible multiplier-effect evidence through the iPSC discovery’s broad follow-on impact across pharmaceutical, clinical, laboratory, regenerative-medicine, cancer, epigenetics, and aging research. The provided evidence also indicates institutional leadership roles at CiRA/CiRA Foundation and advisory roles, but these are from an unknown-independence dossier item and cannot strongly raise the score by themselves. Evidence for capital attraction, founded organizations, policy attention, or documented talent/founder networks is absent.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/shinya-yamanaka"},{"public_id":"celine-halioua","name":"Celine Halioua","tagline":"Biotech founder pursuing the first approved lifespan-extension drugs for dogs","photo_url":"/api/investor-photos/e6c0db32-a9ae-412d-895a-1882ded85159.jpg","photo_checked_at":"2026-09-04 19:30:08.813411+00","primary_role":"entrepreneur","roles":["entrepreneur","scientist"],"role_tags":["entrepreneur","scientist"],"theme_tags":["destination"],"impact_statement":"Celine Halioua founded Loyal and raised $38 million to develop drugs that extend dogs’ lifespan and healthspan, with the aim of applying those lessons to human aging medicines.","overall_score":34,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":8,"rationale_summary":"Halioua articulates a concrete and highly ambitious vision: use approved canine lifespan-extension drugs as a translational and commercial foundation for human aging therapeutics, while building a durable company that popularizes and leads the field. Calling Loyal her life's work strengthens the signal of long-term commitment. The vision falls short of field-defining evidence because no specific human-healthspan target, development timeline, or explicit risk-aware roadmap is provided.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":0,"rationale_summary":"The dimension is applicable because Halioua is a biotech founder, but the supplied evidence identifies no personal investments, donations, or other capital deployment into longevity ventures. Loyal raised external capital, but fundraising and operating a company do not establish that Halioua personally deployed capital or produced an attributable investment outcome.","confidence":"high","n_a_reason":null},{"dimension":"field_creation","score":6,"rationale_summary":"Halioua created Loyal, a substantial biotechnology organization focused on making canine longevity drugs a recognized pharmaceutical category and regulatory pathway. This is meaningful field-building, but the evidence primarily establishes the company and its ambitions—not an approved product, completed regulatory pathway, or demonstrated broader infrastructure adopted by others.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":4,"rationale_summary":"Founding Loyal represents a plausible multiplier mechanism through organization-building and a regulatory strategy that could legitimize longevity therapeutics. However, the supplied evidence does not document realized second-order effects such as attracted capital or talent, policy influence, major collaborations, founder formation, or follow-on projects. The publication record indicates modest scholarly reach but does not establish broader field-building impact.","confidence":"low","n_a_reason":null},{"dimension":"scientific_impact","score":4,"rationale_summary":"The citation record shows credible but still modest scientific influence: an h-index of 6, 95 citations across 14 works, and no clearly field-defining paper. Recent canine-aging studies indicate relevant translational contributions, but their citation impact remains limited or too recent to establish substantial influence on the field.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":7,"rationale_summary":"Halioua made a distinctive, thesis-coherent bet that dogs could provide both a nearer-term market and a regulatory proving ground for approved longevity therapeutics, with lessons later applied to human aging drugs. This is plausibly path-opening and contrarian, but the evidence documents only one major bet and does not establish regulatory approval, commercial success, field-wide influence, or the counterfactual importance needed for a top-band score.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":5,"rationale_summary":"Halioua demonstrates meaningful conviction by undertaking a technically risky, unconventional drug-development program as a first-time solo founder and publicly describing Loyal as her life's work. The evidence supports a significant career-scale bet, but not exceptional personal financial exposure, sustained resistance to serious criticism, self-experimentation, or a documented contrarian stance against mainstream opposition.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/celine-halioua"},{"public_id":"david-gobel","name":"David Gobel","tagline":"Co-founded and leads Methuselah Foundation, which funds prizes, grants, and ventures to extend healthy human lifespan and helped incubate SENS-related work.","photo_url":"/api/investor-photos/0343d41a-80b7-4197-80e7-d182975a143c.jpg","photo_checked_at":"2026-09-22 18:45:15.190385+00","primary_role":"philanthropist","roles":["philanthropist","populariser","entrepreneur"],"role_tags":["philanthropist","populariser","entrepreneur","investor","scientist"],"theme_tags":[],"impact_statement":"Gobel’s direct science record is thin. His real longevity impact is co-founding Methuselah Foundation, an early platform for prizes, grants, projects, and ventures chasing healthy lifespan.","overall_score":34,"total_capital_moved":0,"updated_at":"2026-09-22 18:45:15.190385+00","scores":[{"dimension":"scientific_impact","score":2,"rationale_summary":"Primary citation metrics show very limited direct scientific publication impact: one OpenAlex-indexed work, h-index 1, i10-index 0, and 6 total citations. The available authored work is a 2025 Nature Aging meeting report on aging biomarkers rather than a field-shaping technical paper. Evidence suggests Gobel may have enabled longevity research through Methuselah Foundation, but the provided evidence does not document independently corroborated scientific outputs or specific enabled breakthroughs at a level that would justify a higher scientific-impact score.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":5,"rationale_summary":"Future vision applies, and the evidence shows Gobel co-founded and leads an organization with a concrete longevity goal, especially Methuselah Foundation's public target of making “90 the new 50 by 2030.” However, the provided evidence contains no direct personal vision statements, destination quotes, theory endorsements, or path/timeline/risk explanations from Gobel himself, so the score is moderate rather than high.","confidence":"low","n_a_reason":null},{"dimension":"capital_deployed","score":3,"rationale_summary":"The dimension applies because the evidence describes David Gobel as a co-founder and leader of Methuselah Foundation and CEO of Methuselah Fund, both longevity-focused capital-allocation institutions. However, the evidence provides no disclosed investment or donation amounts, no named transactions or grants, and no primary or independent corroboration of actual capital deployed. This supports some institution-building credit but not a high capital-deployed score.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"The dimension applies: Gobel is presented mainly as an institution-builder through Methuselah Foundation, with evidence of a real longevity platform connected to funding, prizes, grants, ventures, and field collaboration. That supports meaningful second-order leverage, but the supplied record gives little independently corroborated detail on scale, capital attracted, major follow-on projects, or measurable ecosystem effects, so the score should remain moderate rather than high.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":7,"rationale_summary":"David Gobel has credible field-creation evidence through co-founding and leading Methuselah Foundation, a longevity-focused biomedical nonprofit that funds research, ventures, projects, and prizes. The foundation's existence and Gobel's active role are independently corroborated by an academic source listing both Gobel and Methuselah Foundation in the longevity/biomarkers community, satisfying the independence gate for scoring above 5. However, most operational detail about the foundation's specific programs and impact comes from the foundation's own website, and the evidence provided does not independently document the scale or downstream field-wide effects of its prizes, grants, or SENS-related incubation.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":4,"rationale_summary":"The evidence supports some bravery/conviction through early, public commitment to longevity via co-founding Methuselah Foundation in 2001, when the foundation says such work was widely considered foolish and dangerous. However, the record provided is mostly self-published and does not document personal downside, major sacrifice, criticism endured, self-experimentation, or a bet sized relative to Gobel’s capacity, so the score should stay moderate-low with low confidence.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":7,"rationale_summary":"The evidence supports a strong but not definitive strategic_taste score: Gobel appears to have made an early, thesis-coherent, high-risk institution-building bet by co-founding Methuselah Foundation in 2001 to advance healthy lifespan extension through prizes, research funding, project support, and venture incubation. The bet was plausibly contrarian given the supplied claim that healthy life extension was then viewed as foolish or dangerous. However, the record is thin, mostly self-published, and does not provide enough independent counterfactual detail or outcome attribution to justify a top-tier score.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/david-gobel"},{"public_id":"michael-greve","name":"Michael Greve","tagline":"Founder of Forever Healthy and Kizoo, with a public commitment of major capital to rejuvenation biotechnology startups and translational aging interventions.","photo_url":"/api/investor-photos/448d3632-a758-40b6-a3d6-380d9291c7c7.jpg","photo_checked_at":"2026-06-13 01:00:17.867596+00","primary_role":"investor","roles":["investor","philanthropist","entrepreneur"],"role_tags":["investor","philanthropist","entrepreneur","populariser"],"theme_tags":["destination","path"],"impact_statement":"Greve helped make longevity more operational: Forever Healthy pushes intervention reviews and translation of molecular repair research into therapies. The capital claims are thinner than the legend.","overall_score":34,"total_capital_moved":0,"updated_at":"2026-06-25 19:45:28.973456+00","scores":[{"dimension":"future_vision","score":7,"rationale_summary":"Greve has a clear and publicly stated longevity vision centered on a world without age-related diseases and vastly extending healthy lifespan. The evidence shows ambition, durability through Forever Healthy and Kizoo, and some concrete pathway language around prevention, evidence reviews, ecosystem-building, and translation of molecular repair research into therapies. The score is not higher because the evidence does not include detailed personal theory endorsements, timelines, or a highly specific roadmap attributed directly to Greve.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":2,"rationale_summary":"Evidence for scientific impact is sparse and indirect. There are no citation metrics, authored papers, clinical trials, or independently corroborated scientific outputs. The available evidence supports that Greve enabled longevity and rejuvenation efforts through Forever Healthy and Kizoo, but does not demonstrate field-shaping scientific influence or direct technical contributions.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":4,"rationale_summary":"The dimension applies because Greve is presented as founding Forever Healthy and using it for longevity ecosystem-building, evidence reviews, and translational support. However, the only concrete operational evidence is self-published or unknown-independence, and there is no independent corroboration of measurable second-order outcomes such as attracting outside capital, founders, policy attention, major collaborators, or follow-on projects. Under the independence gate, this supports a modest score but not above 5.","confidence":"low","n_a_reason":null},{"dimension":"capital_deployed","score":4,"rationale_summary":"Capital deployment is applicable because the evidence describes Greve as operating Forever Healthy and Kizoo in longevity/rejuvenation biotech, but the record provided contains no disclosed investment or donation amounts, no named portfolio companies or grants, and no primary/independent corroboration of actual capital deployed. The score is therefore capped and confidence is low despite plausible institution-building signals.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":5,"rationale_summary":"The dimension applies because Greve has public longevity deployment activity through Forever Healthy and Kizoo-linked rejuvenation biotech work. The evidence shows a coherent thesis: combine practical near-term health optimization with translation of molecular repair and rejuvenation research into human therapies. That supports moderate strategic taste, especially for thesis coherence and translational focus. However, the evidence is mostly self-published, lacks dates, disclosed investments, stage choices, counterfactual detail, or proof that his bets opened paths others were not seeing, so the score should not be high.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":5,"rationale_summary":"Field creation applies: the evidence supports that Michael Greve founded Forever Healthy, an active longevity-focused organization with initiatives around healthy lifespan extension, intervention reviews, and translation of rejuvenation research. However, the strongest operational and field-building claims come from self-published or unknown-independence sources, so the independence gate prevents a score above 5 without primary or independent corroboration of the achievement or impact.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":7,"rationale_summary":"Greve shows clear bravery/conviction through a substantial pivot from internet entrepreneurship into longevity and rejuvenation biotech, including personal capital deployment, Kizoo investing, and founding Forever Healthy. The evidence supports career sacrifice and magnitude-relative-to-capacity, but does not establish field-defining public risk, sustained criticism, contrarian advocacy under pressure, or personal biological risk-taking.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/michael-greve"},{"public_id":"peter-fedichev","name":"Peter Fedichev","tagline":"Gero founder applying physics to aging.","photo_url":"/api/investor-photos/9bc8ed0a-9e1a-4c05-a125-0320bb4a4811.jpg","photo_checked_at":"2026-05-15 11:57:11.65745+00","primary_role":"entrepreneur","roles":["entrepreneur","scientist"],"role_tags":["entrepreneur","scientist"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Fedichev pushed aging toward physics-style resilience models, not wellness fog. Through Gero and cited aging work, he helped make loss of resilience a testable longevity target.","overall_score":34,"total_capital_moved":0,"updated_at":"2026-06-13 00:03:53.268814+00","scores":[{"dimension":"field_creation","score":4,"rationale_summary":"Field creation applies because Fedichev is described as founding/co-founding Gero, a longevity-focused biotech company using AI, human data, and physics-based models. However, the evidence for founding and broader field-building impact is mostly dossier/structured evidence with limited independent corroboration of the specific organizational achievement or its field-level effects, so the independence gate caps the score well below high.","confidence":"low","n_a_reason":null},{"dimension":"future_vision","score":7,"rationale_summary":"Fedichev has a clear and repeated public vision around materially extending human lifespan by treating aging as an underlying biological/physical process rather than only managing age-related disease. The evidence includes a direct mission statement, multiple mechanistic claims about resilience, entropic damage, biological age, and lifespan limits, plus translational paths through biomarkers, therapeutic targets, and lifespan-extending compounds. The score is not higher because the evidence provided is mostly summarized or company/theory-aligned rather than showing a highly detailed public roadmap with milestones, timelines, or broad field-defining influence.","confidence":"medium","n_a_reason":null},{"dimension":"strategic_taste","score":6,"rationale_summary":"Fedichev shows a coherent and plausibly contrarian strategic thesis: applying physics-informed AI and large-scale longitudinal health data to aging as a systems/resilience problem rather than only a disease-by-disease or hallmarks framework. Founding Gero is a clear deployment vehicle, and the strategy has signs of field-shaping ambition through gerophysics framing, pharma collaborations, and claims of large-scale data infrastructure. However, the evidence is mostly self-published, lacks timing for the original bet, and provides limited independent proof that his choices were early, counterfactually important, or opened paths others were not seeing.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":4,"rationale_summary":"Multiplier effect applies, but the evidence shows only moderate leverage: Fedichev founded Gero and appears to have built a collaborative scientific/company platform around physics-informed aging research. Bibliometrics and multi-author publications support some legitimacy and collaborator attraction, but there is little concrete evidence here of attracting major capital, policy attention, founders, broad public legitimacy, or follow-on projects beyond Gero. Independence-gate support for a higher score is limited.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":7,"rationale_summary":"Primary citation metrics show substantial scientific influence, with h-index 38, 5,533 total citations, and multiple papers above 150 citations. However, the most-cited work is largely in physics/atomic gases rather than longevity, so the aging-specific impact is meaningful but not clearly field-defining.","confidence":"high","n_a_reason":null},{"dimension":"capital_deployed","score":2,"rationale_summary":"Capital deployment is applicable because Fedichev is described as CEO/co-founder of Gero, a longevity-focused biotech company, which is some evidence of institution-building directed at aging. However, the provided evidence contains no disclosed personal investments, donations, fund allocations, or amounts, and the founder/mission claims are largely self-published or only weakly sourced for this dimension.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":4,"rationale_summary":"Peter Fedichev shows some public conviction through strong, arguably controversial scientific claims about aging: framing COVID-19 as a disease of aging, asserting an intrinsic human lifespan limit tied to resilience loss, and publicly committing his founder identity to significantly extending lifespan. However, the evidence does not show major personal downside, sustained criticism, large relative financial risk, or concrete self-experimentation. This supports a modest bravery/conviction score rather than a high one.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/peter-fedichev"},{"public_id":"nir-barzilai","name":"Nir Barzilai","tagline":null,"photo_url":"/api/investor-photos/ab03fdc6-393f-40e0-b9fa-c5cf99c4a866.jpg","photo_checked_at":"2026-05-20 13:00:02.895289+00","primary_role":"scientist","roles":["scientist","entrepreneur","clinician"],"role_tags":["scientist","entrepreneur","clinician","populariser","self-experimenter"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Barzilai helped drag longevity from supplement folklore toward testable geroscience: metformin, metabolic pathways, centenarians, and biomarkers. The citation trail is large; clinical proof is still the hard part.","overall_score":33.83,"total_capital_moved":0,"updated_at":"2026-06-13 00:03:58.796776+00","scores":[{"dimension":"capital_deployed","score":null,"rationale_summary":"The supplied evidence supports Nir Barzilai's scientific activity and aging-research prominence, but does not show deployment of his own capital, philanthropy, investment capital, or institution-building resources toward longevity. Under the rubric, this appears inapplicable rather than merely low-scoring.","confidence":"high","n_a_reason":"No evidence provided of personal capital deployment, donations, fund allocation, or resource-allocation activity; evidence describes him as a scientist/researcher."},{"dimension":"scientific_impact","score":9,"rationale_summary":"Primary citation metrics show very strong scientific influence: h-index 102, 40,606 total citations, and multiple highly cited papers directly tied to aging biology, metformin/aging, centenarians, metabolic pathways, and biomarkers. This supports a near field-defining scientific impact score, though not a perfect 10 because the evidence does not establish his exact contribution level on the most-cited multi-author works and includes no clinical-trial impact signal.","confidence":"high","n_a_reason":null},{"dimension":"future_vision","score":6,"rationale_summary":"Barzilai has articulated a recognizable geroscience vision: target aging itself, shift from disease treatment to health treatment, and develop practical pathways such as biomarkers, clinics/testbeds, and interventions like metformin. The evidence shows durable and specific direction, but it lacks a clear public destination statement, explicit timeline, or detailed end-state vision for ending/reversing aging, limiting the score below top-tier field-defining vision.","confidence":"medium","n_a_reason":null},{"dimension":"strategic_taste","score":3,"rationale_summary":"Strategic_taste applies because there is at least one organizational bet and some evidence of a coherent scientific direction around metabolism, insulin, lipids, metformin, and aging. However, the provided evidence does not document a clear strategic thesis, timing, risk appetite, counterfactual importance, or rationale for CohBar, so the score should remain low despite Barzilai's broader prominence in aging research.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":3,"rationale_summary":"The dimension applies because there is evidence of organization creation, but the provided evidence only supports one founded company and no active organizations or donation-created programs. The independent/primary academic sources establish Barzilai as an aging researcher, but they do not corroborate broader field-building achievements such as creating durable programs, communities, protocols, or funding paths.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":2,"rationale_summary":"The dimension applies, but the provided evidence contains almost no direct support for public risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, or self-experimentation. Barzilai is clearly an influential longevity researcher with substantial scholarly output, including work on metformin and aging, but scientific productivity alone is not evidence of bravery or conviction under this rubric.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"Barzilai shows credible second-order leverage through very high scholarly influence, participation in broad multi-institution geroscience consensus work, and founding CohBar. The evidence supports substantial field legitimacy and collaborator reach, but it is thin on concrete downstream outcomes such as capital attracted, policy change, talent pipelines, founders created, or follow-on projects directly attributable to him.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/nir-barzilai"},{"public_id":"tony-wyss-coray","name":"Tony Wyss-Coray","tagline":"Neuroscientist decoding how systemic aging affects the brain","photo_url":"/api/investor-photos/3157db7f-cf61-4785-823f-dbe3ec37ac16.jpg","photo_checked_at":"2026-09-04 19:30:05.884342+00","primary_role":"scientist","roles":["scientist","entrepreneur"],"role_tags":["scientist","entrepreneur"],"theme_tags":["destination","meta_view","path","risk_view"],"impact_statement":"Wyss-Coray advanced the study of how blood, immune cells, and microbiome metabolites shape brain aging, while developing biological clocks to measure aging across organs and guide healthspan research.","overall_score":33.83,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":7,"rationale_summary":"Wyss-Coray presents a durable, scientifically grounded vision of preserving cognition and extending healthspan by measuring organ-specific aging and therapeutically modifying systemic, immune, and blood-borne drivers of brain decline. The evidence includes concrete targets and research paths, but does not establish a clear timeline, comprehensive strategy for ending aging, or repeated direct public commitment to the most ambitious whole-body lifespan-extension claims.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The record contains no investments, donations, disclosed capital, or backed companies attributable to Tony Wyss-Coray. The cited academic work concerns scientific research and does not make the capital_deployed dimension applicable.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced for this scientist."},{"dimension":"field_creation","score":4,"rationale_summary":"Wyss-Coray is credited with co-founding four companies, including Alkahest, which translated blood-factor research toward neurodegenerative disease. This constitutes relevant field-building, but the evidence does not establish that these ventures created enduring programs, communities, funding paths, or a field-defining category, and none is listed as active.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":5,"rationale_summary":"The evidence suggests a coherent strategy centered on systemic drivers of brain aging and repeated attempts to translate that thesis through early-stage company formation. This indicates focused scientific and entrepreneurial taste, particularly around blood-borne, immune, and microbiome-mediated mechanisms. However, the record does not establish when the bets were made, how contrarian they were, whether Wyss-Coray was counterfactually decisive, or whether the companies produced credible translational outcomes.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":4,"rationale_summary":"Wyss-Coray demonstrated moderate public conviction by co-advocating broader acceptance of parabiosis and policy changes enabling its biomedical use when the approach was described as forgotten and shunned. This supports a contrarian public stance, but the evidence reflects one underlying advocacy action and does not establish major personal risk, career sacrifice, sustained resistance to serious criticism, or self-experimentation.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":3,"rationale_summary":"The supplied citation metrics—the rubric's primary signal—show only 5 citations, an h-index of 1, and no highly cited foundational work. The additional papers demonstrate relevant and potentially important research on brain aging, microglia, parabiosis, microbiome metabolites, and aging clocks, but they are mostly very recent and lack evidence here of substantial citation influence or field-shaping impact.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"Wyss-Coray shows meaningful multiplier effects through company creation and broad scientific collaboration. Most notably, he co-founded Alkahest and is reported as co-founder of three additional companies, indicating translation of research into follow-on organizations. The supplied studies also connect investigators across numerous Stanford units and external institutions. However, only Alkahest has a linked source record, the scale and outcomes of the companies are not documented, and there is no evidence here of field-defining effects on talent, capital, policy, or public legitimacy.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/tony-wyss-coray"},{"public_id":"laura-niedernhofer","name":"Laura Niedernhofer","tagline":"Geroscientist investigating genome instability and healthy aging","photo_url":"/api/investor-photos/583503c4-19b3-4f1b-9761-949921fff0ec.jpg","photo_checked_at":"2026-09-04 20:04:41.489039+00","primary_role":"scientist","roles":["scientist"],"role_tags":["scientist"],"theme_tags":["meta_view","path"],"impact_statement":"Laura Niedernhofer helped establish cellular senescence and senolytics as major lines of aging research. Her 445 works have drawn 32,722 citations, including three cited more than 2,300 times each.","overall_score":33.02,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":4,"rationale_summary":"Niedernhofer has articulated a credible healthspan-oriented vision centered on therapeutic restoration of the aging immune system and advancing geroscience, supported by a substantial research program on senescence and lifespan-extending interventions. However, the evidence does not show a specific destination for human longevity, a development timeline, quantified goals, major risks, or a consistently articulated theory of how aging will ultimately be reversed or overcome.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9.3,"rationale_summary":"Niedernhofer demonstrates field-defining scientific influence in cellular senescence and geroscience. Her h-index of 81, 32,722 citations, and numerous papers with roughly 700–3,300 citations indicate sustained, agenda-shaping impact rather than publication volume alone.","confidence":"high","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The evidence establishes substantial scientific output but provides no capital deployments to evaluate. Scientific publications and citations do not constitute capital-deployment outcomes under this rubric.","confidence":"high","n_a_reason":"No public investment, donation, or other capital-deployment activity is evidenced for this scientist."},{"dimension":"strategic_taste","score":6,"rationale_summary":"Her publication record suggests a coherent and relatively early scientific bet linking DNA damage and cellular senescence to actionable healthspan interventions, particularly senolytics. Highly cited work on senolytic targets and compounds indicates that this direction helped establish an important translational path. However, the evidence does not establish her individual decision-making role, contrarian intent, or a clear counterfactual showing that the path would not have advanced without her.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":3,"rationale_summary":"Niedernhofer holds substantial field-building leadership roles as director of a university aging institute and two research cores, which plausibly provide shared infrastructure for longevity research. However, the evidence does not establish that she founded these entities, created a new program or category, or developed a field-defining community, protocol, or funding path.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":0,"rationale_summary":"The dimension is applicable, but the supplied evidence documents scientific productivity and impact rather than public risk-taking or conviction. No evidence establishes a contrarian stance, career sacrifice, a personally significant bet, persistence under serious criticism, or self-experimentation.","confidence":"high","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"Niedernhofer demonstrates substantial scholarly multiplier effects: a highly cited research portfolio has helped propagate cellular-senescence and senolytic research across aging biology and several clinical domains. However, the evidence does not establish comparable leverage through organization-building, capital, policy, entrepreneurship, or public advocacy.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/laura-niedernhofer"},{"public_id":"emil-kendziorra","name":"Emil Kendziorra","tagline":null,"photo_url":"/api/investor-photos/92e12ffc-e1cb-4540-8e9a-06b9370f8e7c.jpg","photo_checked_at":"2026-05-25 13:00:22.832429+00","primary_role":"entrepreneur","roles":["entrepreneur","scientist","self-experimenter"],"role_tags":["entrepreneur","scientist","self-experimenter"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Kendziorra helped move biostasis from fringe talk into actual institutions and research roadmaps. The science is still speculative; the operator work is the real signal.","overall_score":33,"total_capital_moved":0,"updated_at":"2026-06-13 00:04:04.71493+00","scores":[{"dimension":"multiplier_effect","score":5,"rationale_summary":"Kendziorra shows credible but not field-defining multiplier effect through repeated organization-building in biostasis and participation in multi-author scientific roadmap work. The evidence supports some collaborator/network leverage, but there is little corroborated evidence of attracting major capital, policy attention, broad public legitimacy, founders, or large follow-on projects.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":2,"rationale_summary":"Scientific impact applies, but the primary citation signal is very weak: OpenAlex reports h-index 0, i10-index 0, 0 total citations, and only 1 matched work. The peer-reviewed biostasis papers show participation in setting a speculative research agenda, but there is no evidence of cited, field-shaping scientific output or clinical translation.","confidence":"high","n_a_reason":null},{"dimension":"future_vision","score":7,"rationale_summary":"Kendziorra has a clear and durable public vision centered on biostasis/cryopreservation as a bridge to future restorative or anti-aging technologies, supported by organizational leadership and coauthored roadmap-style publications. The vision is ambitious and reasonably specific, but the evidence lacks direct destination quotes, explicit timelines, and broad field-defining public articulation beyond the cryonics/biostasis frame.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":4,"rationale_summary":"There is credible but limited evidence of public conviction: Kendziorra has built and publicly led organizations around cryonics/biostasis and coauthored papers arguing that speculative brain preservation deserves serious research. However, the evidence does not show clear personal downside, sustained criticism, large capacity-relative sacrifice, or self-experimentation.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":4,"rationale_summary":"The dimension applies because Kendziorra appears to have built or led longevity-adjacent biostasis institutions, but the evidence provides no disclosed personal capital, fund allocation, donations, investment totals, or recurring financial commitments. Institution-building claims support some credit, but not a high capital-deployed score.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":5,"rationale_summary":"Kendziorra shows a coherent and relatively contrarian operator thesis around building cryopreservation, biostasis, and cryotechnology institutions, especially through Tomorrow Bio and related organizations. The evidence supports early, high-risk company formation in an underbuilt longevity-adjacent area, but does not establish strong counterfactual importance, field adoption, commercial traction, or a clearly articulated strategic thesis beyond repeated focus on biostasis.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":6,"rationale_summary":"Kendziorra has credible field-creation evidence through founding or co-founding multiple biostasis/cryonics organizations and contributing to formal research-roadmap work intended to coordinate the field. Primary/independent sources corroborate participation in biostasis roadmap/publication activity, but the organization-founding claims are mostly from structured facts, self-published, or unknown-independence dossier material, so the score should not be pushed into clearly field-defining territory.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/emil-kendziorra"},{"public_id":"daisy-robinton","name":"Daisy Robinton","tagline":"Biotech founder developing therapeutics for ovarian aging and women’s health","photo_url":"/api/investor-photos/bc6f6b49-8dc8-447a-9374-779d9688682c.jpg","photo_checked_at":"2026-09-04 20:03:13.940534+00","primary_role":"entrepreneur","roles":["entrepreneur"],"role_tags":["entrepreneur"],"theme_tags":["destination","timeline"],"impact_statement":"Robinton co-founded Oviva to develop drugs that preserve ovarian function and extend women’s healthspan. Its lead program targets ovarian response, but clinical benefit has not been shown.","overall_score":32.67,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"scientific_impact","score":3,"rationale_summary":"Scientific impact is applicable, but the evidence demonstrates limited realized influence. Robinton co-authored two independent, peer-reviewed longevity papers and helped develop an ovarian-aging therapeutic program, yet neither paper is shown to be foundational or heavily cited, and no clinical validation is provided. The Oviva program appears translationally promising but remains supported mainly by company claims and an acquisition rather than demonstrated scientific or clinical outcomes.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":4,"rationale_summary":"Robinton shows credible but modest multiplier effects through building Oviva around ovarian aging, helping legitimize reproductive longevity as a biotechnology focus, and positioning its program to continue through Granata Bio. However, the evidence does not quantify talent recruitment, capital attracted, policy influence, collaborations generated, or follow-on ventures.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":7,"rationale_summary":"Robinton has articulated a clear, ambitious, and therapeutically grounded vision: delaying menopause by preserving ovarian function to extend women’s healthspan. She identifies a concrete destination, a near-term drug-development pathway, and broader health benefits, but the evidence supports an organ-specific vision rather than a comprehensive strategy for ending aging or dramatically extending human lifespan.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":2,"rationale_summary":"Robinton publicly championed an ambitious and unconventional therapeutic program targeting ovarian aging, but the supplied evidence does not establish career sacrifice, substantial personal risk, persistence under serious criticism, or self-experimentation. Founding the company and articulating its bold vision provide a limited signal of conviction, not strong evidence of rubric-defined bravery.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The evidence establishes scientific and operating involvement in longevity biotechnology, including Oviva Therapeutics, but does not show that Robinton personally deployed capital. Founder activity alone cannot be treated as investment or philanthropy without specific evidence.","confidence":"high","n_a_reason":"No public investment, donation, or other capital-deployment activity is evidenced for Daisy Robinton."},{"dimension":"strategic_taste","score":6,"rationale_summary":"Robinton made a coherent, relatively early company-building bet that ovarian aging is both a tractable therapeutic target and a driver of female healthspan beyond fertility. Oviva and OVI-586 demonstrate thesis-to-program alignment, and the transition to Granata Bio offers a plausible continuation path. However, the evidence does not establish clinical validation, field-level influence, a strong counterfactual case, or that Robinton uniquely opened this path.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":6,"rationale_summary":"Robinton co-founded a biotechnology company that established a concrete therapeutic program around ovarian aging and reproductive longevity, helping make an underdeveloped longevity area more legible. Independent sources corroborate Oviva Therapeutics' existence and her association with it, but the evidence does not show that she created a broader field-wide category, coalition, protocol, or funding path with demonstrated uptake by others.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/daisy-robinton"},{"public_id":"steven-austad","name":"Steven Austad","tagline":"Comparative biologist studying the evolution of health and longevity","photo_url":"/api/investor-photos/c2615ea2-92c0-433e-b15f-be7714fe851b.jpg","photo_checked_at":"2026-09-04 20:03:21.416632+00","primary_role":"scientist","roles":["scientist"],"role_tags":["scientist"],"theme_tags":["destination","meta_view"],"impact_statement":"Austad made comparative biology a major tool for aging research, using long-lived mammals to probe why species age differently. His 313 papers have drawn more than 16,000 citations.","overall_score":32.43,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":6,"rationale_summary":"Austad articulates a credible, durable geroscience vision centered on understanding aging well enough to develop interventions that slow age-related health decline. He also identifies practical requirements for progress, including reliable health assays, standardized outcome measures, and separate evaluation of lifespan, healthspan, and morbidity. However, the evidence does not show a specific development roadmap, timeline, intervention target, or consistent commitment to ending aging or reversing decline.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":8.8,"rationale_summary":"Strong, independently corroborated scientific influence in comparative biology and aging. An h-index of 66, more than 16,000 citations, and multiple papers with several hundred to nearly 1,800 citations indicate sustained agenda-setting impact across aging evolution, sex differences in lifespan, telomeres, and comparative mammalian longevity.","confidence":"high","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The evidence establishes Austad's scientific output but identifies no investments, donations, investees, disclosed capital, catalytic positions, or capital-backed longevity outcomes. Capital deployed is therefore genuinely inapplicable on the supplied record.","confidence":"high","n_a_reason":"No public capital deployment activity is evidenced for this academic scientist."},{"dimension":"strategic_taste","score":6,"rationale_summary":"Austad shows a sustained, thesis-coherent commitment to comparative and evolutionary biology as a way to uncover determinants of aging. His early studies of unusually long-lived mammals and populations plausibly represented a distinctive research bet and became influential. However, the supplied evidence does not establish explicit counterfactual importance, unusual risk-taking, precise strategic choices among alternatives, or that his work opened paths others were not pursuing.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":1,"rationale_summary":"Field creation is applicable, but the supplied evidence establishes scholarly contributions rather than the creation of organizations, programs, categories, communities, protocols, or funding paths. The structured facts explicitly report no founded organizations or donation-created programs.","confidence":"high","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension is applicable, but the supplied evidence documents a substantial conventional research career rather than public risk-taking or costly conviction. None of the five qualifying bravery flavors is established.","confidence":"high","n_a_reason":null},{"dimension":"multiplier_effect","score":5,"rationale_summary":"Austad shows meaningful second-order influence through a large, highly cited research portfolio and collaborations spanning multiple institutions and comparative-aging topics. This suggests his work has shaped subsequent scholarship and attracted collaborators, but the supplied evidence does not demonstrate organization-building, talent pipelines, capital mobilization, policy influence, public legitimacy gains, or identifiable follow-on initiatives at a scale supporting a higher score.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/steven-austad"},{"public_id":"gregory-fahy","name":"Gregory Fahy","tagline":"Cryobiologist pioneering thymus regeneration and immune rejuvenation","photo_url":"/api/investor-photos/b24a6373-1b2e-47d3-be15-015ad155b295.png","photo_checked_at":"2026-09-04 20:03:15.489402+00","primary_role":"scientist","roles":["scientist","operator"],"role_tags":["scientist","operator"],"theme_tags":["destination","path"],"impact_statement":"Fahy reported early human evidence of partial thymic regeneration and identified cryopreservation as a key requirement for organ banking. The thymus result came from one informal case.","overall_score":32.08,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":7,"rationale_summary":"Fahy has articulated an ambitious, technically specific vision in which tissue engineering, stem-cell-derived organs, and organ banking could dramatically increase median life expectancy, alongside exploration of radical life extension. His sustained work on thymic regeneration, caloric-restriction mimetics, and cryopreservation gives this vision durable scientific grounding. However, the evidence does not establish a detailed timeline, comprehensive roadmap for ending aging, or repeated explicit public commitments to that ultimate goal.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":2,"rationale_summary":"Fahy publicly pursued unconventional thymic-regeneration and organ-cryopreservation research, including reporting an informal human intervention, which provides a limited signal of scientific conviction. However, the evidence does not establish that he was the volunteer, personally accepted risk, sacrificed career or capital, faced serious criticism, or persisted despite documented opposition.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":5,"rationale_summary":"Fahy has credible scientific output spanning thymic regeneration, caloric-restriction mimetics, and cryopreservation, including early human evidence and translationally relevant research. However, no citation metrics are available to establish field-defining influence, and the thymic-regeneration evidence presented is primarily a single-subject, informal study. The record supports meaningful scientific contribution but not a high-impact score under a citation-first rubric.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":3,"rationale_summary":"Fahy’s research helped articulate organ banking as an enabling technology for transplantation and regenerative medicine, and his publications demonstrate sustained collaboration across institutions. However, the evidence does not establish substantial second-order outcomes such as attracting capital or talent, building organizations or coalitions, influencing policy, inspiring founders, or generating documented follow-on programs.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"This dimension is inapplicable on the provided record. The structured facts identify zero investments and zero donations, with no independently rated investees or capital-backed longevity outcomes. Fahy's research and company affiliations do not establish that he personally deployed capital.","confidence":"high","n_a_reason":"No public investment, donation, or other capital-deployment activity is evidenced for Fahy; the supplied sources document scientific work rather than financing outcomes."},{"dimension":"strategic_taste","score":6.5,"rationale_summary":"Fahy showed early, contrarian scientific taste by pursuing human thymic regeneration in 2003 and framing cryopreservation as a critical regenerative-medicine bottleneck in 2006. These choices were thesis-coherent with extending healthy lifespan through immune restoration and organ replacement infrastructure. However, the evidence does not establish a broader selection strategy, strong validation, field-wide adoption, or a clear counterfactual showing that these bets materially redirected longevity research.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":4,"rationale_summary":"Fahy helped establish a distinctive human thymus-regeneration research protocol and led the TRIIM trial, making immune rejuvenation a more concrete longevity research direction. However, the evidence does not show that he founded an organization, built a broad community or funding pathway, or achieved field-defining adoption beyond his research program.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/gregory-fahy"},{"public_id":"kristen-fortney","name":"Kristen Fortney","tagline":null,"photo_url":"/api/investor-photos/53c8f154-454d-4c11-a2db-ff59d03de1a1.jpg","photo_checked_at":"2026-05-27 13:45:08.762941+00","primary_role":"entrepreneur","roles":["entrepreneur","scientist"],"role_tags":["entrepreneur","scientist"],"theme_tags":["destination","meta_view","path","timeline"],"impact_statement":"Fortney helped drag aging biology toward drug development: BioAge plus 50 papers, 1,614 citations, and work on aging biomarkers and drug networks. Not a miracle claim; a real translational footprint.","overall_score":32,"total_capital_moved":0,"updated_at":"2026-06-13 00:04:12.335442+00","scores":[{"dimension":"scientific_impact","score":6,"rationale_summary":"Kristen Fortney has credible direct scientific impact in longevity and computational biology, anchored by primary OpenAlex metrics: h-index 20, 1,614 citations, 50 works, and several aging/longevity-related papers with meaningful citation counts. This indicates solid influence on biomarkers of aging, longevity genetics, and drug/network biology, but the citation profile is moderate rather than field-defining.","confidence":"high","n_a_reason":null},{"dimension":"bravery_conviction","score":2,"rationale_summary":"The dimension applies, but the provided evidence shows mainly longevity-sector leadership and research involvement, not clear public risk-taking, contrarian advocacy, sacrifice, criticism endured, or personal risk. Co-founding and leading BioAge suggests some conviction in translating aging biology into therapies, but the evidence does not establish meaningful downside or bravery under the rubric.","confidence":"low","n_a_reason":null},{"dimension":"future_vision","score":7,"rationale_summary":"Fortney has a clear and consistent translational geroscience vision: use human aging biology, multi-omics data, biomarkers, longevity studies, and drug-development protocols to identify interventions for age-related disease and potentially slow aging. The vision is concrete and durable, but the evidence is more platform/pathway-oriented than a field-defining public manifesto for ending aging or reversing decline.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":3,"rationale_summary":"There is limited evidence of longevity-relevant institution building through Fortney's role as co-founder and CEO of BioAge, but no disclosed personal capital, donations, fund allocations, investment amounts, or independently corroborated capital deployment are provided. The dimension applies, but the evidence supports only a low score.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":3,"rationale_summary":"Strategic taste applies because Fortney founded/co-founded a longevity-related biotech company, BioAge, and her earlier work shows a coherent technical orientation toward aging biomarkers, computational biology, drug repurposing, and translational aging biology. However, the provided evidence does not establish a clear public thesis, timing, contrarianity, stage/risk preferences, or counterfactual importance of her strategic choices. The strongest case is pattern coherence from computational aging biology into company-building, but the evidence is too thin to support a high score.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":6,"rationale_summary":"Fortney has credible field-creation evidence through founding/co-founding BioAge/BioAge Labs, a company aimed at developing therapies for age-related conditions by targeting human aging biology. Independent academic sources corroborate BioAge's role in longevity-relevant translational research, including age-specific COVID-19 therapeutic work and aging biomarker validation. However, the evidence is sparse, partly duplicative, and does not show broader field-defining infrastructure, community creation, protocols, or funding pathways.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":5,"rationale_summary":"Fortney has credible multiplier-effect evidence through company-building around BioAge/BioAge Labs and a moderately cited scientific record that likely contributes public legitimacy and follow-on translational activity. However, the provided evidence does not document concrete second-order outcomes such as capital attracted, major talent networks, policy influence, collaborator ecosystems, founder spinouts, or field-wide institutional leverage, so the score should not exceed the midrange.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/kristen-fortney"},{"public_id":"andrei-seluanov","name":"Andrei Seluanov","tagline":"Comparative biologist studying genome stability in long-lived mammals","photo_url":"/api/investor-photos/588b3713-ff51-4f4e-8699-38ea8a0706d3.jpg","photo_checked_at":"2026-09-04 19:30:08.82062+00","primary_role":"scientist","roles":["scientist"],"role_tags":["scientist"],"theme_tags":["path"],"impact_statement":"Seluanov helped link LINE1 transposable-element activity to age-related inflammation and traced naked-mole-rat cancer resistance to hyaluronan, a mechanism now being tested for therapeutic use.","overall_score":31.5,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":3,"rationale_summary":"The evidence shows a credible mechanistic research direction—linking cGAS loss, chromatin disruption, transposable-element activation, inflammation, and accelerated aging—and an example of translating comparative-biology findings toward therapy. However, it does not establish that Seluanov has publicly articulated a concrete, durable vision for ending aging, reversing biological decline, or materially extending healthy human lifespan.","confidence":"low","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The evidence establishes substantial scientific activity but identifies zero investments, donations, catalytic positions, or capital-backed longevity outcomes. Scientific publications and citations do not constitute capital deployment, so this dimension is inapplicable rather than merely low-scoring.","confidence":"high","n_a_reason":"No public investment, donation, or other capital-deployment activity is evidenced for this scientist."},{"dimension":"field_creation","score":2,"rationale_summary":"Field creation is applicable, but the evidence shows Seluanov participating in established aging-research structures rather than creating a new organization, program, category, community, protocol, or funding path. His executive-committee role and participation in a major collaborative project indicate some field-supporting activity, but not demonstrated field-building leadership.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"Seluanov demonstrates meaningful second-order leverage primarily through broad scholarly influence and extensive cross-institutional collaboration. His highly cited research has helped propagate work on genome stability, cancer resistance, and comparative longevity, while large multi-author projects show an ability to convene or participate in substantial research networks. However, the evidence does not establish organization-building, capital mobilization, policy influence, public legitimacy, or attributable follow-on ventures, limiting the score.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9,"rationale_summary":"Seluanov demonstrates field-defining scientific influence in genome stability, transposable elements, DNA repair, inflammation, and comparative cancer resistance. His h-index of 73 and nearly 20,000 citations are reinforced by numerous heavily cited papers, including several directly central to aging biology. The evidence supports exceptional academic impact, though not the very highest score because authorship-specific contributions and broader field-wide leadership are not independently detailed.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":6,"rationale_summary":"Seluanov shows a coherent scientific bet on learning from unusually long-lived mammals, connecting comparative biology to genome stability, cancer resistance, and potential translation. The naked-mole-rat hyaluronan program is a particularly distinctive choice that produced an influential mechanistic finding and later a therapeutic path. However, the supplied evidence does not establish when or why he formed this thesis, how contrarian it was at inception, or whether his choices were counterfactually decisive for the field.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension is applicable, but the supplied evidence documents scientific productivity rather than public risk-taking or conviction. No qualifying bravery exhibit, career sacrifice, sustained stand under criticism, personally significant bet, or self-experimentation is shown.","confidence":"high","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/andrei-seluanov"},{"public_id":"luigi-ferrucci","name":"Luigi Ferrucci","tagline":null,"photo_url":"/api/investor-photos/69d919a7-e12f-469c-95a8-1af70ae6d712.png","photo_checked_at":"2026-05-27 13:45:02.51206+00","primary_role":"scientist","roles":["scientist","operator"],"role_tags":["scientist","operator"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Ferrucci helped make aging measurable: frailty, gait speed, inflammation, sarcopenia, and aging biomarkers became harder to hand-wave. Not immortality. Actual gerontology.","overall_score":31.5,"total_capital_moved":0,"updated_at":"2026-06-13 00:04:26.873153+00","scores":[{"dimension":"scientific_impact","score":10,"rationale_summary":"Citation-weighted evidence is exceptionally strong: OpenAlex reports an h-index of 240, 280,079 total citations, and multiple heavily cited works central to gerontology, frailty, physical function, inflammation, sarcopenia, and biomarkers of aging. This supports field-defining scientific impact rather than mere publication volume.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":3,"rationale_summary":"Strategic taste is applicable because Ferrucci appears to have shaped research programs and scientific directions, but the provided evidence contains almost no explicit strategy evidence: no thesis, notable bets, stage/risk/horizon preferences, funding choices, or counterfactual claims. The strongest signal is a coherent long-term focus on geroscience, frailty, inflammation, biomarkers, and longitudinal aging research, with very high downstream citation impact, but this supports scientific influence more than clearly documented strategic bet-making.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":1,"rationale_summary":"The dimension applies, but the provided evidence does not show Luigi Ferrucci creating organizations, programs, categories, communities, protocols, or funding paths that made longevity work more legible or possible for others. The evidence mainly shows participation in aging-related research and institutional affiliations, not field-creation activity.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":5,"rationale_summary":"Ferrucci has articulated a coherent geroscience/precision-geromedicine vision focused on identifying individualized aging trajectories and modifying them through gerointerventions, supported by work on frailty, biomarkers, inflammation, resilience, and functional decline. However, the evidence frames the vision mainly as clinical gerontology and aging-trajectory modification, not a broad public program to end aging, reverse decline comprehensively, or radically extend lifespan. Specificity is moderate, ambition is moderate, and public consistency is only lightly evidenced here.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The evidence establishes Luigi Ferrucci as a prominent aging researcher and NIA Scientific Director, but provides no disclosed capital deployed, donations, investments, or specific funding allocations attributable to him. Under the rubric, this appears inapplicable rather than merely low-scoring.","confidence":"high","n_a_reason":"No credible evidence of personal capital, philanthropy, investments, fund allocation, or disclosed institution-building resource deployment."},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension is applicable, but the provided evidence contains almost no direct support for public risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, or self-experimentation. Ferrucci is clearly a highly established aging researcher and NIA scientific leader, but scientific stature alone is not evidence of bravery or conviction under this rubric.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Ferrucci shows strong second-order leverage through exceptionally high scholarly uptake and repeated participation in highly cited, multi-institutional aging work, suggesting broad collaborator and follow-on research effects. However, the evidence does not show organization-building, capital attraction, policy leadership, founder creation, or public legitimacy activity beyond the scientific ecosystem, so the score is strong but not field-defining for this specific dimension.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/luigi-ferrucci"},{"public_id":"mehmood-khan","name":"Mehmood Khan","tagline":"Physician-executive mobilizing global capital for healthspan science","photo_url":"/api/investor-photos/d42f3f79-60ea-4148-a2d2-a9cb7f4d7d56.png","photo_checked_at":"2026-09-11 19:45:06.513086+00","primary_role":"philanthropist","roles":["philanthropist","operator","scientist"],"role_tags":["philanthropist","operator","scientist","populariser"],"theme_tags":["destination","meta_view","path","risk_view"],"impact_statement":"Khan pushed geroscience toward clinical translation by calling for new funding models and helping convene the 2023 Global Healthspan Summit.","overall_score":31.5,"total_capital_moved":0,"updated_at":"2026-09-11 19:45:06.513086+00","scores":[{"dimension":"strategic_taste","score":4,"rationale_summary":"Khan articulates a coherent thesis that geroscience is entering a capital-intensive translational phase poorly served by conventional funding, and that grantmaking and investment should address this gap. This shows strategic framing, but the evidence does not identify specific early or contrarian allocations, demonstrate catalytic decision-making, or establish counterfactual field impact.","confidence":"low","n_a_reason":null},{"dimension":"scientific_impact","score":3,"rationale_summary":"There is credible evidence of direct scientific authorship, including clinical research involving older adults and a recent aging-brain publication, but the strongest bibliometric evidence appears misattributed to Hassan Khan rather than Mehmood Khan. The remaining evidence does not establish field-defining scientific influence.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":1,"rationale_summary":"The dimension applies because Khan leads a grantmaking and investment foundation, but the supplied evidence identifies no specific investments, donations, catalytic positions, or independently rated investees. Therefore, no credible, human-trial-stage longevity outcome can be attributed to his capital deployment. The academic sources establish aging-related activity, not capital outcomes.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":5,"rationale_summary":"Khan demonstrates meaningful public conviction by challenging acceptance of aging as inevitable and advocating nontraditional, large-scale funding for geroscience. Leading an organization with up to $1 billion in annual funding makes the institutional bet consequential, but the evidence does not establish personal financial exposure, career sacrifice, sustained action under serious criticism, or self-experimentation.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":6,"rationale_summary":"Khan is credibly associated with building Hevolution Foundation as a new funding path for geroscience and with convening the Global Healthspan Summit. Independent academic records attest that both the foundation and summit exist, satisfying the field-building independence gate. However, the evidence does not establish the scale, durability, funding outcomes, or Khan's precise personal role strongly enough for a field-defining score.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":5,"rationale_summary":"Khan leads a real foundation focused on mobilizing funding for geroscience and has helped convene a global healthspan summit, giving him credible field-building leverage beyond direct research. However, the evidence does not quantify capital deployed or demonstrate resulting talent recruitment, collaborations, companies, policy changes, or follow-on projects.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":7.5,"rationale_summary":"Khan presents a clear and ambitious healthspan vision centered on treating aging as a biological condition, shifting medicine toward prevention, and accelerating therapies through sustained scientific funding. The vision includes actionable mechanisms but lacks a defined timeline, measurable end state, or detailed scientific theory of change.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/mehmood-khan"},{"public_id":"jim-mellon","name":"Jim Mellon","tagline":"Co-founded Juvenescence and publicly framed longevity as an investable biotechnology thesis through the book Juvenescence and substantial company-building activity.","photo_url":"/api/investor-photos/6a1557ff-bc15-41f1-8528-34839d70db75.png","photo_checked_at":"2026-06-12 23:00:02.427976+00","primary_role":"entrepreneur","roles":["entrepreneur","investor","philanthropist"],"role_tags":["entrepreneur","investor","philanthropist","scientist"],"theme_tags":["meta_view","path","timeline"],"impact_statement":"Mellon helped make longevity biotech legible as a company category, mainly through Juvenescence and field-definition papers. Scientific footprint: modest, not mythical.","overall_score":31,"total_capital_moved":0,"updated_at":"2026-06-13 00:04:32.623256+00","scores":[{"dimension":"capital_deployed","score":3,"rationale_summary":"The dimension applies because Mellon is described as an investor and company-builder in longevity, but the provided evidence contains no high- or medium-confidence disclosed investment amounts, donation amounts, named longevity investments, or independently corroborated capital deployment. Evidence supports involvement with Juvenescence and the longevity biotech ecosystem, but not the scale of his own capital at risk.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":6,"rationale_summary":"Strategic taste applies: the evidence shows Mellon helped make longevity biotechnology legible as an investable and company-buildable field, especially through Juvenescence and public framing around the longevity biotech category. This supports a moderately strong score for thesis formation and field-shaping positioning, but the record provided is thin on timing, contrarianism, specific portfolio choices, counterfactual importance, capital allocation, and outcomes, which limits confidence and prevents a higher score.","confidence":"medium","n_a_reason":null},{"dimension":"field_creation","score":5,"rationale_summary":"The dimension applies because Mellon is tied to creating at least one longevity-focused company, Juvenescence, which plausibly helped make longevity biotechnology more legible as an investable field. However, the provided evidence is thin for field creation: it lists two founding-role facts for the same organization and one independent academic citation showing Mellon affiliated with Juvenescence in the aging/longevity conference ecosystem, but it does not independently document Juvenescence's broader field-building impact, category creation, funding pathway creation, or downstream influence. Under the independence gate, the independent source supports participation/affiliation in the field but only weakly corroborates the claimed achievement, so a score above 5 is not justified from this evidence alone.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":3,"rationale_summary":"The evidence supports visible public and company-building conviction in longevity biotechnology, especially through co-founding and leading Juvenescence and backing longevity-related companies. However, the provided evidence does not establish public contrarian risk-taking, meaningful sacrifice, a bet sized relative to his capacity, persistence under serious criticism, or personal self-experimentation. This warrants a low-to-moderate score rather than N/A.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"Mellon has credible multiplier-effect evidence through co-founding Juvenescence and helping make longevity biotechnology more institutionally legible, with independent/primary evidence of participation in field-defining or standard-setting publications alongside major longevity biotech actors. However, the provided evidence does not quantify capital attracted, talent recruited, companies created beyond duplicated Juvenescence entries, policy influence, or follow-on projects attributable to him specifically, so the score should not be higher.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":6,"rationale_summary":"Mellon has a clear public longevity vision at the level of sector thesis and company-building: aging biology is investable, therapeutically targetable, and can be advanced through biotechnology, AI-enabled discovery, biomarkers, and longevity-company infrastructure. The evidence supports durable and public consistency through Juvenescence, coauthored field-definition and biomarker papers, and ecosystem activity. However, the provided record lacks strong destination-style quotes, explicit timelines, or a detailed personal roadmap for ending aging or materially extending healthy lifespan, so this is substantial but not field-defining vision evidence.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":2,"rationale_summary":"The citation_metrics source is the primary signal and shows limited direct scientific impact: h-index 2, i10-index 2, 68 total citations, and only 3 works. Mellon appears as a coauthor on longevity biotech framing/recommendation papers rather than as a field-defining scientific contributor. The evidence supports some enabled or agenda-setting contribution to the longevity biotech field, but not substantial scientific influence by citation weight.","confidence":"high","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/jim-mellon"},{"public_id":"daniel-belsky","name":"Daniel Belsky","tagline":"Population scientist measuring the pace and causes of biological aging","photo_url":"/api/investor-photos/3c2997e5-3f87-4471-8431-90dc3c466f63.png","photo_checked_at":"2026-09-04 20:03:14.576016+00","primary_role":"scientist","roles":["scientist"],"role_tags":["scientist"],"theme_tags":["meta_view","path"],"impact_statement":"Belsky helped make the pace of biological aging measurable through tools including DunedinPoAm and BioAge. His work has shaped a widely cited research agenda for testing aging interventions.","overall_score":30.33,"total_capital_moved":0,"updated_at":"2026-09-05 00:15:56.810963+00","scores":[{"dimension":"future_vision","score":3,"rationale_summary":"Belsky articulates a credible research path centered on measuring biological aging, identifying upstream determinants, and evaluating modifiable processes and interventions. However, the evidence does not show a concrete, ambitious destination for ending aging, reversing biological decline, or materially extending healthy lifespan, nor a timeline or consistently endorsed theory of how that destination will be reached.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":null,"rationale_summary":"The dimension is inapplicable on the supplied record. Structured facts identify zero investments and zero donations, while the cited evidence concerns research and scholarly impact rather than deployed capital.","confidence":"high","n_a_reason":"No public evidence of investment, donation, or other capital-deployment activity; Belsky is represented here solely as an academic scientist."},{"dimension":"field_creation","score":1,"rationale_summary":"The dimension is applicable, but the supplied evidence does not show that Belsky founded an organization, program, community, coalition, funding path, or other field-building infrastructure. The cited work demonstrates participation in collaborative aging research, including methodological harmonization and an interactive research portal, but does not establish that he created or led either initiative.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":7,"rationale_summary":"Belsky demonstrates substantial scholarly multiplier effects: his biological-aging measures and related research have generated extensive citation uptake and enabled broad, multi-institutional follow-on work. The evidence supports strong influence on collaborators and subsequent research, but not comparable leverage through organizations, capital, policy, founder formation, or public movements.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":9,"rationale_summary":"Belsky demonstrates major, field-shaping scientific influence, with an h-index of 73 and 26,608 citations. His impact is especially strong in biological-aging measurement: foundational work on quantifying aging in young adults, DunedinPoAm, biomarker comparisons, and BioAge has accumulated hundreds to more than 1,000 citations per paper and helped establish a technical agenda around measuring the pace of aging.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":6,"rationale_summary":"Belsky’s sustained program of measuring aging longitudinally—especially quantifying biological aging in young adults and developing pace-of-aging biomarkers—shows a coherent scientific thesis that opened useful paths for studying causes and interventions before late-life disease emerges. Strong citation uptake supports field relevance, but the evidence does not establish that these choices were unusually contrarian, uniquely early, or counterfactually decisive.","confidence":"medium","n_a_reason":null},{"dimension":"bravery_conviction","score":0,"rationale_summary":"The evidence establishes substantial scientific productivity in aging research but does not document public risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, a personally consequential bet, or self-experimentation.","confidence":"low","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/daniel-belsky"},{"public_id":"michael-d-west","name":"Michael D. West","tagline":"Founded or led Geron, Advanced Cell Technology, BioTime/Lineage-related efforts, and AgeX, connecting telomere biology, stem cells, and regenerative medicine to human longevity goals.","photo_url":"/api/investor-photos/3c4fb005-3b03-4226-99e4-72319c07ad9c.png","photo_checked_at":"2026-06-05 22:45:12.596862+00","primary_role":"scientist","roles":["scientist","entrepreneur"],"role_tags":["scientist","entrepreneur"],"theme_tags":["destination","meta_view","path","risk_view"],"impact_statement":"West helped drag longevity from supplement folklore toward cell biology: telomerase, cell immortality, cloning, and embryonic stem-cell derivatives. Human life-extension proof is not there.","overall_score":30,"total_capital_moved":0,"updated_at":"2026-06-13 00:04:37.913459+00","scores":[{"dimension":"scientific_impact","score":8,"rationale_summary":"Michael D. West has strong direct scientific-impact evidence anchored by primary citation metrics: h-index 48, 18,514 total citations, and multiple highly cited works in telomerase, cell immortality, cloning, and embryonic stem-cell-derived tissues. The top telomerase paper alone has 7,143 citations, with another telomerase-related work at 2,249 citations, indicating field-shaping influence rather than mere publication volume. The evidence supports substantial scientific agenda-setting in telomere biology and regenerative medicine, though not a maximum score because the provided evidence does not show clinical-trial translation and several listed later works appear more programmatic or review/interview-oriented than independently field-defining.","confidence":"high","n_a_reason":null},{"dimension":"multiplier_effect","score":6,"rationale_summary":"The strongest evidence for multiplier effect is scholarly leverage: very high citation metrics and multiple heavily cited telomerase/stem-cell works indicate substantial follow-on research attention. There is also some independent evidence of participation in broader aging-research consensus activity. However, the provided evidence does not substantiate organizational founding, capital attraction, talent networks, policy impact, or specific downstream ventures, so the score should not be higher.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":8,"rationale_summary":"The evidence shows a clear, ambitious, and fairly specific longevity vision: using telomere biology, pluripotency/reprogramming, embryonic regeneration pathways, and scalable young-cell manufacturing to slow or reverse aspects of biological aging and treat age-related disease. The vision is concrete and mechanistic rather than merely aspirational, with repeated statements about reversing cell aging, restoring regenerative capacity, and translating these ideas into therapies. It falls short of a 9-10 because the evidence provided is mostly technical/academic and does not show a broadly field-defining public manifesto, explicit roadmap, or strong independent evidence of long-term public consistency beyond the cited statements.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":2,"rationale_summary":"The dimension applies because West is presented as a company founder/leader in longevity-adjacent biotechnology, but the provided evidence contains no disclosed investments, donations, personal capital at risk, fund allocations, or quantified institution-building resources. The only relevant signal is leadership/affiliation with BioTime and a large-scale stem-cell initiative, which supports some organizational commitment but not capital deployment.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":2,"rationale_summary":"The dimension is applicable because West publicly worked in longevity-adjacent areas such as telomerase, embryonic stem cells, regenerative medicine, and anti-aging research. However, the provided evidence contains no explicit bravery exhibits, no self-experimentation, and little direct evidence of public risk-taking, sacrifice, criticism endured, or contrarian advocacy. The score is therefore low, with limited credit for visible participation in early anti-aging and regenerative-medicine programs that had human-longevity relevance.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":3,"rationale_summary":"Strategic taste applies, but the provided evidence contains little direct strategy evidence. The strongest signal is a coherent technical orientation around telomerase, cellular immortality, embryonic stem cells, cloning, and regenerative medicine, plus participation in BioTime's ACTCellerate initiative. However, the evidence does not substantiate specific early bets, founding decisions, capital allocation, counterfactual importance, or a clear strategy profile.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":1,"rationale_summary":"The dimension applies, but the provided evidence does not substantiate creation of organizations, programs, categories, communities, protocols, or funding paths. The strongest available item only places Michael D. West among authors on a broad aging-research article, which is not evidence of field-creation activity by him.","confidence":"low","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/michael-d-west"},{"public_id":"abolishaging","name":"Anar Isman","tagline":null,"photo_url":"/api/investor-photos/0f494cd8-5698-40cf-a53c-8a6bece55752.jpg","photo_checked_at":"2026-05-25 13:00:18.558773+00","primary_role":"entrepreneur","roles":["entrepreneur","scientist","investor"],"role_tags":["entrepreneur","scientist","investor"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Isman’s impact is practical, not mythic: AgelessRx-linked studies put off-label rapamycin, LDN/NAD+, and QoL endpoints into real-world longevity data. Useful work; not field conquest.","overall_score":29,"total_capital_moved":0,"updated_at":"2026-06-13 00:04:44.698153+00","scores":[{"dimension":"strategic_taste","score":4,"rationale_summary":"The evidence shows a coherent and contrarian public thesis: aging and death are framed as neglected, upstream society-level problems, and AgelessRx suggests a translational strategy aimed at making longevity interventions accessible. However, the record is thin on early timing, counterfactual importance, investment judgment, stage selection, or concrete strategic decisions beyond advocacy and company leadership, so the strategic-taste score should remain modest with low confidence.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":5,"rationale_summary":"The dimension applies because there is evidence Anar Isman founded AgelessRx, an organization active in real-world geroscience/longevity intervention studies. Primary academic sources corroborate AgelessRx-affiliated work on off-label rapamycin, LDN/NAD+ for post-COVID fatigue, and real-world evidence/QoL endpoints for geroscience trials. However, the evidence does not clearly show that Isman personally created a field-defining category, protocol, community, or funding path beyond founding one company, and the founder fact itself is only described as seeded from a linked investor dossier rather than independently documented here. Score is capped at 5 because the strongest organization-creation claim lacks primary or independent corroboration in the provided evidence.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":4,"rationale_summary":"The dimension applies because Isman founded AgelessRx and appears to have helped create a platform that generated collaborations and follow-on clinical/real-world evidence work in longevity. The evidence shows some second-order leverage through coauthored studies involving AgelessRx and external academic or institutional collaborators, but it does not establish major capital attraction, policy influence, broad founder/talent creation, or field-defining legitimacy.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":3,"rationale_summary":"Scientific impact applies, but citation-weighted evidence indicates an early/modest research footprint rather than field-defining influence. OpenAlex shows h-index 7, 153 total citations, and most-cited work at 59 citations, with publications mainly in real-world rapamycin/healthspan cohorts and a small long-COVID fatigue pilot. These are relevant to longevity science but not yet heavily cited or agenda-setting at the field level.","confidence":"high","n_a_reason":null},{"dimension":"future_vision","score":7,"rationale_summary":"Anar Isman has repeatedly articulated an ambitious public vision centered on abolishing/curring aging and treating aging/death as society-level problems. The evidence shows clear commitment and consistency, including a durable profile slogan, pinned framing, and recent posts tying longevity to survival and major disease risk. However, the vision is more advocacy-oriented than technically concrete: there is little evidence of a specific roadmap, timelines, mechanistic theory, or detailed strategy for ending aging beyond ecosystem involvement and healthspan-oriented rapamycin work.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":2,"rationale_summary":"The dimension applies because there is a claimed investor/connector role and an institution-building signal via CEO affiliation with AgelessRx, but the provided evidence contains no disclosed investments, donations, funding amounts, or independently corroborated capital deployment by Anar Isman. The strongest relevant evidence is self-published or unknown-independence affiliation/activity, so it supports only a low score with low confidence.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":4,"rationale_summary":"Anar Isman has credible but mostly self-published evidence of public conviction: he frames aging and death as critically overlooked societal problems and adopts a highly visible anti-aging identity. The evidence supports contrarian stance and some personal visibility/commitment, but does not show major career sacrifice, large financial risk, sustained criticism, or concrete risky self-experimentation.","confidence":"medium","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/abolishaging"},{"public_id":"bryan-johnson","name":"Bryan Johnson","tagline":null,"photo_url":"/api/investor-photos/462e2b6d-56fa-44e3-a79a-5a7e3b3cd5d7.jpg","photo_checked_at":"2026-05-15 19:45:02.861684+00","primary_role":"self-experimenter","roles":["self-experimenter","populariser","entrepreneur"],"role_tags":["self-experimenter","populariser","entrepreneur","investor"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Johnson made longevity louder by turning his own protocol into media, a Don’t Die campaign, and an Rx platform. The hard evidence for field-building or scientific impact is thin.","overall_score":28,"total_capital_moved":420000000,"updated_at":"2026-06-13 00:05:00.553257+00","scores":[{"dimension":"capital_deployed","score":3,"rationale_summary":"The dimension applies because Bryan Johnson is presented as an entrepreneur/investor and longevity public figure, but the provided evidence contains no high- or medium-confidence disclosed investments, donations, or amounts deployed toward longevity. The strongest signals are institution-building claims around Blueprint/Don't Die and a self-published launch of a longevity prescription platform, which suggest some operational commitment but do not establish scale of capital deployed.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":5,"rationale_summary":"The evidence supports a moderate bravery/conviction score primarily through public self-experimentation and visibility: Johnson publicly ties a longevity prescription platform to medications he says he personally uses, and presents a broad anti-death/longevity stance publicly. However, the supplied evidence does not substantiate stronger forms such as major career sacrifice, large relative financial risk, sustained conviction under serious criticism, or a clearly documented contrarian stand against mainstream opposition.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":2,"rationale_summary":"Bryan Johnson has some direct scientific authorship evidence in cancer biology papers related to senescence and melanoma mechanisms, but the strongest citation-metrics block appears mismatched to another researcher and high-energy-physics work, so it cannot credibly support a high scientific-impact score for him. The remaining evidence supports limited direct scientific contribution rather than field-defining impact.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":4,"rationale_summary":"The dimension applies: the evidence suggests Johnson is trying to create second-order leverage through a longevity Rx platform, health-product partnerships, and media/cultural distribution. However, the concrete multiplier achievements are supported almost entirely by self-published X posts, with little independent or primary corroboration of actual talent attraction, capital mobilization, policy attention, durable collaborators, or follow-on projects. Under the independence gate, this cannot justify a score above 5.","confidence":"low","n_a_reason":null},{"dimension":"future_vision","score":8,"rationale_summary":"Bryan Johnson has a highly public, durable, and ambitious future vision centered on defeating death and popularizing longevity through Blueprint and the Don't Die movement. The vision is clear and consistently messaged, with some concrete deployment pathways such as a longevity prescription platform, but the evidence provided is lighter on detailed scientific roadmap, timelines, risk handling, or directly endorsed mechanistic theories, which keeps it below field-defining maximum strength.","confidence":"medium","n_a_reason":null},{"dimension":"strategic_taste","score":4,"rationale_summary":"The evidence shows a coherent and high-risk strategy around translating Johnson's personal longevity protocol into consumer-facing products, medical access, partnerships, and media narrative. However, the record here is mostly self-published, very recent, and thin on early timing, counterfactual importance, field-level impact, or evidence that these choices opened paths others were not seeing.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":2,"rationale_summary":"The dimension applies, but the provided evidence only weakly supports field creation. The structured facts say Bryan Johnson founded one company, Minicircle, but it is listed as inactive and there is no supplied primary or independent corroboration showing that it created a durable organization, protocol, community, category, or funding path that made longevity work more possible for others.","confidence":"low","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/bryan-johnson"},{"public_id":"james-peyer","name":"James Peyer","tagline":"Biotech builder translating aging biology into a portfolio of medicines","photo_url":"/api/investor-photos/d4d88339-88a9-4c4c-8134-41d0c70a867e.jpg","photo_checked_at":"2026-09-11 19:45:03.634666+00","primary_role":"entrepreneur","roles":["entrepreneur","scientist"],"role_tags":["entrepreneur","scientist"],"theme_tags":["destination","meta_view"],"impact_statement":"Peyer founded Cambrian Bio to turn aging biology into a portfolio of medicines. He also coauthored papers defining longevity biotech and proposing shared biomarker practices for trials.","overall_score":28,"total_capital_moved":0,"updated_at":"2026-09-11 19:45:03.634666+00","scores":[{"dimension":"future_vision","score":7,"rationale_summary":"Peyer has articulated a durable geroscience vision: develop preventive medicines that target aging biology upstream of chronic disease and thereby extend healthspan. His leadership of a multi-asset biotechnology company, repeated public endorsement of this thesis, and coauthorship of field-defining and biomarker-focused papers make the vision credible and actionable. The evidence does not establish a concrete timeline, quantitative lifespan goal, or comprehensive roadmap for ending aging, limiting a higher score.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":1,"rationale_summary":"The dimension applies because Peyer leads a multi-asset biotechnology company, but the supplied evidence identifies no investments, donations, deployed amounts, catalytic positions, or independently rated investees. Consequently, there is no demonstrated capital-backed longevity outcome under the rubric's credibility-and-human-trials gate. His Cambrian affiliation and longevity scholarship establish field involvement, not successful capital deployment.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":7,"rationale_summary":"Peyer helped build field infrastructure through founding Cambrian Bio and coauthoring publications that define the longevity-biotechnology category and propose shared biomarker practices for clinical trials. Independent academic sources corroborate Cambrian's existence and his participation in these field-legibility efforts, but the evidence does not establish broad adoption, measurable ecosystem impact, or that the two listed organizations are genuinely distinct.","confidence":"medium","n_a_reason":null},{"dimension":"multiplier_effect","score":4,"rationale_summary":"Peyer has credible but limited multiplier effects through founding and leading Cambrian and contributing moderately cited work that helps define longevity biotechnology. Independent evidence confirms his Cambrian affiliation, and his publications have attracted some scholarly attention. However, the record does not demonstrate the scale of talent or capital attracted, collaborators mobilized, companies spawned, policy influence, or follow-on projects, so a stronger ecosystem-level score is not justified.","confidence":"medium","n_a_reason":null},{"dimension":"scientific_impact","score":4,"rationale_summary":"Peyer has credible but modest scientific influence. His h-index of 4 and 107 total citations do not indicate field-defining impact, although two recent longevity-biotechnology papers have attracted meaningful attention and may help shape the field's translational agenda.","confidence":"high","n_a_reason":null},{"dimension":"strategic_taste","score":4,"rationale_summary":"Peyer demonstrates a coherent strategic thesis: translate aging-biology discoveries into medicines through a multi-asset biotechnology company. This is relevant strategic deployment, but the evidence does not show when or why specific programs were selected, whether the bets were early or contrarian, what alternatives he rejected, or whether Cambrian opened paths others had overlooked. The available record therefore supports moderate thesis coherence but not a high score for demonstrated judgment or counterfactual importance.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":1,"rationale_summary":"The dimension applies because Peyer publicly leads a longevity-focused biotechnology company, but the supplied evidence does not document any qualifying act of bravery or conviction under the rubric. His authorship on longevity-biotechnology papers shows visible engagement with the field, yet it does not establish a contrarian stance, meaningful personal or career sacrifice, a capacity-relative bet, persistence under serious criticism, or self-experimentation.","confidence":"high","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/james-peyer"},{"public_id":"kai-micah-mills","name":"Kai Micah Mills","tagline":null,"photo_url":"/api/investor-photos/f7141ca7-8ded-46cb-93fc-c58e1dc12398.jpg","photo_checked_at":"2026-05-15 11:57:17.576741+00","primary_role":"entrepreneur","roles":["entrepreneur","populariser","investor"],"role_tags":["entrepreneur","populariser","investor"],"theme_tags":["destination","meta_view","path","risk_view","timeline"],"impact_statement":"Mills has pushed longevity toward cryonics infrastructure, not wellness theater, by building Cryopets and CryoDAO and publicly framing death as a technical problem. Evidence is thin; this is movement-building, not proven impact yet.","overall_score":28,"total_capital_moved":100000,"updated_at":"2026-06-13 00:04:49.924555+00","scores":[{"dimension":"scientific_impact","score":2,"rationale_summary":"The dimension applies because Mills is presented as a cryonics/decentralized-science founder, but the provided evidence contains no citation metrics, authored papers, clinical trials, or independently corroborated scientific outputs. The strongest claims are entrepreneurial or planned research activity, mostly self-published, so there is only weak evidence of direct or enabled scientific impact to date.","confidence":"low","n_a_reason":null},{"dimension":"bravery_conviction","score":4,"rationale_summary":"There is moderate evidence of public contrarian conviction around anti-deathist, cryonics-adjacent longevity views, plus visible entrepreneurial commitment to cryopreservation through Cryopets and CryoDAO. However, the evidence is mostly self-published, recent, and does not show major professional sacrifice, sustained criticism, large personal financial risk, or direct self-experimentation such as a personal cryonics commitment. This supports a real but not high bravery_conviction score.","confidence":"medium","n_a_reason":null},{"dimension":"future_vision","score":7,"rationale_summary":"Mills has a clear and publicly repeated future vision centered on cryopreservation as a route to preventing death, preserving identity-relevant information, and enabling future repair or revival. The vision is ambitious and tied to concrete mechanisms and projects, especially CryoDAO research on memory cryopreservation and CryoPets' biostasis framing. However, the evidence is mostly self-published or summarized, with limited destination-style quotes, timelines, or detailed public roadmaps for ending aging or extending healthy lifespan beyond cryonics.","confidence":"medium","n_a_reason":null},{"dimension":"capital_deployed","score":2,"rationale_summary":"There is some evidence that Kai Micah Mills has directed entrepreneurial and organizational effort toward cryonics/longevity through Cryopets, CryoDAO, and related roles, but the provided evidence shows no disclosed investments, donations, grant amounts, fund allocations, or verified personal capital deployed. The capital-deployed case is therefore weak and mostly based on self-published founder claims rather than corroborated funding activity.","confidence":"low","n_a_reason":null},{"dimension":"strategic_taste","score":5,"rationale_summary":"Mills shows a coherent, high-risk strategic thesis around cryonics, cryopreservation, memory preservation, and anti-deathist movement-building. The strongest signal is organization-building around CryoDAO and Cryopets plus a stated technical bet on complex memory cryopreservation with Greg Fahy. However, the evidence is almost entirely self-published, very recent, and lacks proof of execution, field uptake, funding scale, or demonstrated counterfactual importance, so the score should remain moderate with low confidence.","confidence":"low","n_a_reason":null},{"dimension":"field_creation","score":4,"rationale_summary":"Field creation applies because Mills is credited with founding or co-founding cryonics/decentralized-science organizations, especially Cryopets and CryoDAO. However, the evidence is thin, mostly self-published or independence-unknown, includes duplicated organization entries, and the structured facts say none of the founded organizations are active. Without primary or independent corroboration of durable programs, communities, protocols, funding paths, or field-level adoption, the score should remain below the independence-gate cap.","confidence":"low","n_a_reason":null},{"dimension":"multiplier_effect","score":4,"rationale_summary":"Multiplier effect applies because Mills is presented as a founder/movement-builder around cryonics organizations, with evidence of multiple organizations, public narrative work, and planned research collaboration. However, nearly all corroboration is self-published or unknown-independence, so the independence gate prevents a score above 5. The evidence supports some leverage through organization-building and public legitimacy efforts, but not independently verified attraction of capital, talent, policy attention, or major follow-on projects.","confidence":"low","n_a_reason":null}],"public_url":"https://eternalsearch.net/heroes/kai-micah-mills"}],"pagination":{"total":77,"limit":50,"offset":0,"has_more":true},"access_level":"public"}